showing 7348 abstracts


results from 'International Association for the Study of Lung Cancer' where authors matches anything




Details title year
Details OA01.05 PHASE II STUDY OF NEO-ADJUVANT CHEMO/ IMMUNOTHERAPY FOR RESECTABLE ... 2018
Details MA22.11 RISK OF HIPPOCAMPAL METASTASES IN SMALL CELL LUNG CANCER: IMPLICAT... 2018
Details P1.05-22 NEW METHODS OF BRACHYRADIOTHERAPY CATHETER STABILIZATION IN THE A... 2018
Details P1.16-63 THE VALUE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH RESECTED STAG... 2018
Details P2.06-40 VISTA IS HIGHLY EXPRESSED IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)... 2018
Details P2.17-31 THE EFFECT OF THE EXTENDED BILATERAL MEDIASTINAL LYMPH NODE DISSE... 2018
Details P3.11-21 THE DEVELOPMENT OF A ROBUST RADIOLOGY QUALITY ASSURANCE (QA) PROG... 2018
Details OA01.06 DETERRED: PHASE II TRIAL COMBINING ATEZOLIZUMAB CONCURRENTLY WITH... 2018
Details MA22.09 SHOULD STEREOTACTIC RADIOSURGERY BE CONSIDERED FOR SALVAGE OF INTR... 2018
Details P1.05-20 THERAPEUTIC CONDITION OF PHOTODYNAMIC THERAPY USING TARAPORFIN SO... 2018
Details P1.16-61 INTERMITTENT CHEST TUBE CLAMPING SHORTENS CHEST TUBE DURATION AFT... 2018
Details P2.06-41 DIFFERENTIATING SARCOMATOID MESOTHELIOMA FROM PLEOMORPHIC CARCINO... 2018
Details P2.17-32 DYNAMIC MONITORING BEFORE AND AFTER NEO- ADJUVANT CRIZOTINIB IN NO... 2018
Details P3.11-23 ADHERENCE TO ANNUAL LOW-DOSE CT LUNG CANCER SCREENING AT A LARGE ... 2018
Details OA02.03 CLINICAL ACTIVITY OF LORLATINIB IN PATIENTS WITH ROS1+ ADVANCED NO... 2018
Details MA23.01 BUFFY COAT IMMUNOONCOLOGIC DIAGNOSIS AND PROGNOSIS OF PSTAGE I LUN... 2018
Details P1.05-21 CT-GUIDED BIOPSY OF LUNG LESIONS WITH OUTER CANNULA WASHING CYTOL... 2018
Details P1.17-02 LOW PROGNOSTIC NUTRITIONAL INDEX PREDICTS POOR SURVIVAL IN STAGE ... 2018
Details P2.06-39 NEXT GENERATION SEQUENCING REVEALS GENETIC LANDSCAPE OF MALIGNANT... 2018
Details P2.17-33 ROLE OF ADJUVANT THERAPY IN PULMONARY ADENOSQUAMOUS CARCINOMA... 2018
Details P3.11-24 “TO KNOW OR NOT TO KNOW .?” PUSH AND PULL IN EVER SMOKERS LUN... 2018
Details OA02.01 EFFICACY AND SAFETY OF ENTRECTINIB IN LOCALLY ADVANCED OR METASTAT... 2018
Details MA23.05 POST-OPERATIVE RADIATION IMPROVES OVERALL SURVIVAL IN PATIENTS WIT... 2018
Details P1.05-24 CLINICAL CHARACTERISTICS AND PROGNOSTIC ANALYSIS OF MULTIPLE PRIM... 2018
Details P1.16-64 THE HISTOLOGICAL PREDOMINANT PATTERN COULD PREDICT SITE OF RECURR... 2018
Details P2.09-01 TUMOR-ASSOCIATED IMMUNE CELL INFILTRATION PATTERNS IN EARLY STAGE... 2018
Details P3.01-02 PATIENTS WITH A SMALLER PRIMARY TUMOR AND FEWER METASTASES COULD ... 2018
Details P3.11-26 RESULTS OF INITIAL LOW-DOSE COMPUTED TOMOGRAPHIC SCREENING FOR LU... 2018
Details OA02.02 SAFETY AND PRELIMINARY CLINICAL ACTIVITY OF ROPOTRECTINIB (TPX-000... 2018
Details MA23.02 CIRCULATING TUMOR DNA ANALYSIS WITH A NOVEL VARIANT CLASSIFIER FOR... 2018
Details P1.09-01 PD-L1 TESTING ON NSCLC CYTOLOGY SAMPLES IN A UK TEACHING HOSPITAL... 2018
Details P1.17-01 ROBUSTNESS OF AN IMAGE-BASED DATA MINING APPROACH IN LUNG CANCER ... 2018
Details P2.09-02 COMPREHENSIVE ASSESSMENT OF PD-L1 IMMUNOHISTOCHEMISTRY ON PAIRED ... 2018
Details P3.01-03 THE COST BENEFIT FROM SECOND LINE IMMUNOTHERAPY IN METASTATIC NSC... 2018
Details P3.11-25 ANALYSIS INDICATES LOW INCREMENTAL COST- EFFECTIVENESS RATIO FOR I... 2018
Details OA02.05 CK-101 (RX518), A THIRD GENERATION MUTANT-SELECTIVE INHIBITOR OF E... 2018
Details MA23.03 RISK ASSESSMENT FOR INDETERMINATE PULMONARY NODULES USING A NOVEL,... 2018
Details P1.05-23 EVALUATION OF THE 8TH EDITION OF THE TNM CLASSIFICATION FOR LUNG ... 2018
Details P1.17-05 ACCELERATED RADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER: A 12 YEA... 2018
Details P2.06-42 AXL, C-MET AND VEGFR2 TYROSINE KINASE RECEPTORS AS THERAPEUTIC TA... 2018
Details P3.01-01 PROSPECTIVE COMPARISON OF FOUR PLASMA TESTING PLATFORMS FOR T790M... 2018
Details P3.12-02 DYNAMICS OF DLL3 AND ASCL1 EXPRESSION IN SCLC OVER DISEASE COURSE... 2018
Details OA02.06 A PHASE II TRIAL OF POZIOTINIB IN EGFR AND HER2 EXON 20 MUTANT NON... 2018
Details MA23.07 DEFINING THE ROLE OF ADJUVANT THERAPY FOR EARLY STAGE LARGE CELL N... 2018
Details P1.09-03 CHALLENGES IN PD-L1 IMMUNOEXPRESSION IN LIQUID BASED CYTOLOGY SAM... 2018
Details P1.17-03 POTENTIAL ASSOCIATED SNPS BY GWAS WITH RADIATION PNEUMONITIS (RP)... 2018
Details P2.09-04 PD-L1 EXPRESSION IN PRIMARY LUNG ADENOCARCINOMA AND ITS RELATION ... 2018
Details P3.01-05 MATURE PROGRESSION-FREE SURVIVAL IN STAGE IV NON- SMALL CELL LUNG ... 2018
Details P3.12-03 TARGETING DLL3 WITH AMG 757, A BITE ® ANTIBODY CONSTRUCT, AND A... 2018
Details OA03.01 THE IMMUNOPHENOTYPING AND GENOMIC CHARACTERISTICS OF PULMONARY SAR... 2018
Details MA23.06 SMALL RESIDUAL SETUP ERRORS AFTER IMAGE-GUIDED RADIOTHERAPY AFFECT... 2018
Details P1.09-02 PD-L1 EXPRESSION PATTERN IN LARGE CELL NEUROENDOCRINE CARCINOMA O... 2018
Details P1.17-04 CURATIVE INTENT TREATMENT FOR STAGE III NSCLC IN ENGLAND... 2018
Details P2.09-05 EVALUATION OF PD-L1-STAINED TUMOR CELLS VIA THE 22C3 AND SP-142 A... 2018
Details P3.01-06 CONCOMITANT PLASMA-GENOTYPED T790M POSITIVITY AND SMALL CELL CARC... 2018
Details P3.11-27 LUNG CANCER DIAGNOSED AT AGE 50-54 YEARS: SURVIVAL AS POOR AS OLD... 2018
Details OA03.02 NATIONWIDE COMPARATIVE STUDY OF PD-L1 IHC ASSAYS ON LUNG CANCER: I... 2018
Details MA23.10 CONE-BEAM COMPUTED TOMOGRAPHY-GUIDED MICROCOIL LOCALIZATION OF PUL... 2018
Details P1.09-06 THE INCIDENCE OF PD-L1 IN NSCLC AND ITS CORRELATION WITH DRIVER M... 2018
Details P1.17-08 GENETIC PREDICTORS OF RESPONSE TO CHEMORADIATION IN STAGE III NON... 2018
Details P2.09-03 RAPID-IMMUNOCYTOCHEMISTRY FOR EVALUATION OF SURGICAL MARGIN IN SU... 2018
Details P3.01-04 IMMUNE CHECKPOINT INHIBITORS (ICIS) IN NSCLC: IMMUNE RELATED ADVE... 2018
Details P3.12-01 TARGETING MITOCHONDRIAL METABOLISM AS A SELECTIVE THERAPEUTIC APP... 2018
Details OA02.07 UPDATED RESULTS OF PHASE 1 STUDY OF DS-8201A IN HER2-EXPRESSING OR... 2018
Details MA23.09 MINIMALLY INVASIVE APPROACHES DO NOT COMPROMISE OUTCOMES FOR PNEUM... 2018
Details P1.09-04 OPTIMIZATION OF PD-L1 TESTING SPECIMEN FLOW IN THE GREATER HAMILT... 2018
Details P1.17-06 SALVAGE SURGERY AFTER CHEMOTHERAPY AND/OR RADIOTHERAPY INCLUDING ... 2018
Details P2.09-06 EXPRESSION OF PD-L1 ON ROUTINE NON-SMALL CELL LUNG CARCINOMA SECT... 2018
Details P3.01-08 GENDER DIFFERENCES IN LUNG CANCER SURVIVAL... 2018
Details P3.12-05 THE PATTERN OF PD-L1 EXPRESSION IN THORACIC NEUROENDOCRINE TUMORS... 2018
Details OA03.05 CHARACTERIZATION OF THE IMMUNOLOGIC INTRA- TUMOR HETEROGENEITY IN E... 2018
Details MA23.11 LOBE-SPECIFIC NODAL DISSECTION FOR CLINICAL STAGE I AND II NON-SMA... 2018
Details P1.09-05 WHY DOES PD-L1 (22C3) EXPRESSION RATE SHOW DIFFERENCE AMONG REGIO... 2018
Details P1.17-10 CONSOLIDATION CHEMOTHERAPY IN STAGE III NON-SMALL CELL LUNG CANCE... 2018
Details P2.09-09 PRECISION AND REPEATABILITY OF VENTANA DLL3 (SP347) ASSAY IMMUNOH... 2018
Details P3.01-07 OUTCOME AND PROGNOSTIC FACTORS IN ALK+VE METASTATIC ADENOCARCINOM... 2018
Details P3.12-06 SLFN11 EXPRESSION AND EFFICACY OF PARP INHIBITOR THERAPY IN EXTEN... 2018
Details OA03.03 PHASE 2B OF BLUEPRINT PD-L1 IMMUNOHISTOCHEMISTRY ASSAY COMPARABILI... 2018
Details MA24.01 GENOMIC EVOLUTION TRAJECTORY DEPICTS INVASIVENESS ACQUISITION FROM... 2018
Details P1.09-09 EVALUATION OF A NOVEL ROS1 IMMUNOHISTOCHEMISTRY CLONE (SP384) FOR... 2018
Details P1.17-11 PATTERN AND SURVIVAL IMPACT OF NEOADJUVANT TREATMENT OF NON-SMALL... 2018
Details P2.09-07 DOES METASTATIC SITE MATTER FOR PD-L1 TESTING IN STAGE IV NSCLC?... 2018
Details P3.01-11 DEPRESSION AND INFLAMMATION IN PATIENTS WITH EGFR-MUTATED NON-SMA... 2018
Details P3.12-04 LINC00173 MODULATES CHEMORESISTANCE OF SMALL CELL LUNG CANCER BY ... 2018
Details OA03.07 THREE-DIMENSIONAL IMMUNOFLUORESCENCE ANALYSIS OF DYNAMIC VESSEL CO... 2018
Details MA24.03 BIOLOGIC PROFILING OF PRE-METASTATIC NICHE IN COMPLETELY RESECTED ... 2018
Details P1.09-07 PD-L1 PROTEIN EXPRESSION IS A PREDICTOR OF BENEFIT FROM ADJUVANT ... 2018
Details P1.17-09 V30 MAY BETTER PREDICT RADIATION PNEUMONITIS AFTER INTENSITY-MODU... 2018
Details P2.09-08 CLINICAL OUTCOMES OF HISTOLOGY VERSUS CYTOLOGY PD-L1 22C3 ANTIBOD... 2018
Details P3.01-09 IMPACT OF URBAN OR RURAL RESIDENCE ON OVERALL SURVIVAL FOR PATIEN... 2018
Details P3.12-09 SMAD4 MUTATION CONFERS ACQUIRED NEUROENDOCRINE PHENOTYPE IN TRANS... 2018
Details OA03.06 EXTRACTION OF RADIOMIC VALUES FROM LUNG ADENOCARCINOMA WITH NEAR-P... 2018
Details MA24.02 GENOMIC ALTERATIONS IN LUNG ADENOCARCINOMA PRECURSOR LESIONS... 2018
Details P1.09-08 INTEGRATING NGS INFORMATION FOR STAGING MULTIPLE LUNG ADENOCARCIN... 2018
Details P1.17-12 COLLEAGUE PEER REVIEW OF RADICAL LUNG RADIOTHERAPY TREATMENT PLAN... 2018
Details P2.09-12 EGFR MUTATION STATUS IN SQUAMOUS CELL CARCINOMA OR NON-SMALL CELL... 2018
Details P3.01-10 DYSPNEA AS A PROGNOSTIC FACTOR IN HISPANIC PATIENTS WITH NON-SMAL... 2018
Details P3.12-07 MICRORNA DEREGULATION IN A TYPICAL CARCINOID TUMOR: POTENTIAL ROL... 2018
Details OA04.02 DEMOGRAPHIC, PSYCHOSOCIAL, AND BEHAVIORAL ASSOCIATIONS WITH CANCER... 2018
Details MA24.05 BASELINE SPATIAL HETEROGENEITY OF T790M IN TYROSINE KINASE INHIBIT... 2018
Details P1.09-11 IMMUNOHISTOCHEMICAL ASSESSMENT OF BRCA1 ASSOCIATED PROTEIN-1 (BAP... 2018
Details P1.17-13 THE ROLE OF POST-OPERATIVE RADIATION THERAPY IN PATIENTS WITH LOC... 2018
Details P2.09-10 QRT-PCR AS AN EFFICIENT AND RELIABLE DIAGNOSTIC SCREENING APPROAC... 2018
Details P3.01-14 MTORC1 REGULATES THE RADIOSENSITIVITY OF NSCLC CELLS WITH WILDTYP... 2018
Details P3.12-08 THE ROLE OF CONTACTIN 1 ON ACQUIRED RESISTANCE TO PEGYLATED ARGIN... 2018
Details OA04.01 WHAT IS THE COST OF A STRONG EVIDENCE FOR THE TREATMENT OF ADVANCE... 2018
Details MA24.06 LONG NON-CODING RNA EXPRESSION PATTERNS DELINEATE INFILTRATING IMM... 2018
Details P1.09-12 SIMULTANEOUS PLATFORM OF GENOTYPING EGFR, ALK, AND ROS1 IN PATIEN... 2018
Details P1.17-16 CORRELATION OF TUMOR VOLUME REDUCTION DURING NEOADJUVANT CHEMORAD... 2018
Details P2.09-11 TMB ESTIMATED WITH TARGETED NGS IN EARLY STAGE SQUAMOUS CELL CARC... 2018
Details P3.01-12 EGFR MUTATION AND TARGETED THERAPIES: DIFFICULTIES AND DISPARITIE... 2018
Details P3.12-11 ASSOCIATION OF THE LUNG IMMUNE PROGNOSTIC INDEX (LIPI) WITH OUTCO... 2018
Details OA04.06 PERCEPTIONS OF NON-PARTICIPATION IN A REHABILITATION INTERVENTION ... 2018
Details MA24.10 INTERROGATING THE METABOLIC EFFECTS OF KEAP1 INACTIVATION IN ADENO... 2018
Details P1.09-10 TARGETED SEQUENCING OF PULMONARY ENTERIC ADENOCARCINOMA REVEALS D... 2018
Details P1.17-14 OUTCOMES OF HYPOFRACTIONATED RADIATION THERAPY (HFRT) WITH CONCUR... 2018
Details P2.09-13 CORRELATION OF ROS1 (SP384) IMMUNOHISTOCHEMISTRY WITH ROS1 REARRA... 2018
Details P3.01-13 PROGNOSIS OF NON-DRIVER, NEVER SMOKER METASTATIC NON-SMALL LUNG C... 2018
Details P3.12-10 IMMUNOGENOMIC CHARACTERISTICS OF SCLC AND LCNEC REDEFINED MOLECUL... 2018
Details OA04.07 EARLY INITIATED POSTOPERATIVE REHABILITATION REDUCES FATIGUE IN PA... 2018
Details MA24.11 LOSS OF TUMOUR SUPPRESSORS IS ADEQUATE AND SUFFICIENT TO DRIVE LUN... 2018
Details P1.09-14 ANALYSIS OF REAL-WORD MUTATIONS OF LUNG CANCER DRIVER GENES IN 30... 2018
Details P1.17-15 PERIOPERATIVE PROGNOSTIC NUTRITION INDEX FOR INDUCTION CHEMORADIO... 2018
Details P2.09-14 THE DETECTION OF EGFR GENE MUTATION FROM WASHING SOLUTION OF DEVI... 2018
Details P3.01-17 LONG SURVIVORS WITH ADVANCED LUNG CANCER - EFFICACY AND TOLERABI... 2018
Details P3.12-13 EXPRESSION OF THE IMMUNE CHECKPOINT AXIS-PVR/ TIGIT IN SMALL CELL ... 2018
Details OA04.05 AN EARLY REHABILITATION INTERVENTION FOR ENHANCING OXYGENATION FRO... 2018
Details MA24.07 A NOVEL CIS-ACTING LNCRNA CONTROLS HMGA1 EXPRESSION IN LUNG ADENOC... 2018
Details P1.09-13 DETECTION OF ACTIONABLE MUTATIONS IN PLASMA CFDNA SAMPLES FROM NS... 2018
Details P1.17-19 CORRELATION OF DOSIMETRIC AND CLINICAL FACTORS WITH RADIATION PNE... 2018
Details P2.09-17 A CALL TO ACTION: RAPID COLLECTION OF POST-MORTEM LUNG CANCER TIS... 2018
Details P3.01-15 EFFICACY OF PACLITAXEL PLUS TS1 AGAINST NON-SMALL CELL LUNG CANCE... 2018
Details P3.12-14 GENOMIC PROFILING OF CHINESE SMALL CELL LUNG CANCER AND THE IMPLI... 2018
Details OA05.02 EPACADOSTAT PLUS PEMBROLIZUMAB IN PATIENTS WITH NON-SMALL CELL LUN... 2018
Details MA24.09 SYNERGY BETWEEN THE KEAP1/NRF2 AND PI3K PATHWAYS DRIVES NON-SMALL ... 2018
Details P1.09-17 CTNNB1 (BETA-CATENIN) MUTATIONS IN NON-SMALL CELL LUNG CARCINOMA:... 2018
Details P1.17-20 EXCLUDING PTV FROM LUNG VOLUME MAY BETTER PREDICT RADIATION PNEUM... 2018
Details P2.09-15 A NEXT GENERATION SEQUENCING (NGS) RNA-SCAN MULTIPLEX PANEL (QIAS... 2018
Details P3.01-16 LOW DOSE APATINIB COMBINED WITH EGFR-TKI IN TREATING ADVANCED NSC... 2018
Details P3.12-12 GENOMIC PROFILING OF PULMONARY LARGE-CELL NEUROENDOCRINE CARCINOM... 2018
Details OA05.01 EFFICACY/SAFETY OF ENTINOSTAT (ENT) AND PEMBROLIZUMAB (PEMBRO) IN ... 2018
Details MA25.02 SEARCHING FOR A DEFINITION OF SYNCHRONOUS OLIGOMETASTATIC (SOMD)-N... 2018
Details P1.09-15 PRELIMINARY EXPERIENCE WITH LIQUID BIOPSIES IN A RESOURCE CONSTRA... 2018
Details P1.17-17 THE IMPACT OF INDUCTION CHEMORADIOTHERAPY FOLLOWED BY SURGERY FOR... 2018
Details P2.09-16 HETEROGENEITY ANALYSES OF MSLCS——ESPECIALLY IN THE EGFR MUTAT... 2018
Details P3.01-20 ADVANCED NSCLC TREATMENT AND OUTCOMES AFTER NIVOLUMAB... 2018
Details P3.12-16 PROGNOSTIC IMPACT OF M DESCRIPTORS OF THE 8 TH EDITION OF TNM CL... 2018
Details OA05.03 SAFETY AND CLINICAL ACTIVITY OF ADOPTIVE CELL TRANSFER USING TUMOR... 2018
Details MA25.01 EORTC LUNG CANCER GROUP SURVEY TO DEFINE SYNCHRONOUS OLIGOMETASTAT... 2018
Details P1.09-16 NOVEL SOMATIC GENE MUTATION OF SLC17A9, DETECTED IN EARLY-STAGE L... 2018
Details P1.17-18 TREATMENT FOR PATIENTS WITH T4 SUPERIOR SULCUS NON-SMALL CELL LUN... 2018
Details P2.09-20 MINOR COMPONENTS OF SOLID PATTERN IS A SIGNIFICANT POOR PROGNOSTI... 2018
Details P3.01-18 COMPARISON OF PD-L1 IMMUNOHISTOCHEMICAL ASSAYS AND CLINICAL RESPO... 2018
Details P3.12-17 A RETROSPECTIVE STUDY EXAMINING THE ROLE OF PET-CT IN THE 8 TH T... 2018
Details OA05.05 AVELUMAB VS DOCETAXEL FOR PREVIOUSLY TREATED ADVANCED NSCLC: PRIMA... 2018
Details MA25.05 CHARACTERISTICS & SURVIVAL OF RESECTED STAGE IV NON-SMALL CELL LUN... 2018
Details P1.09-19 POSITIVE CORRELATION BETWEEN WHOLE GENOMIC COPY NUMBER VARIANT SC... 2018
Details P2.01-02 OSIMERTINIB FOR EGFR-POSITIVE ADVANCED NSCLC WITH BRAIN METASTASE... 2018
Details P2.09-18 A CLINICOPATHOLOGIC ANALYSIS OF PULMONARY SCLEROSING PNEUMOCYTOMA... 2018
Details P3.01-19 SEQUENCING OF RAMUCIRUMAB+DOCETAXEL POST- IMMUNE CHECKPOINT INHIBI... 2018
Details P3.12-15 68 GA DOTA PET/CT IN STAGING OF BRONCHO- PULMONARY CARCINOID TUMOR... 2018
Details OA05.06 CHECKMATE 227: PATIENT-REPORTED OUTCOMES OF FIRST-LINE NIVOLUMAB +... 2018
Details MA25.03 DEFINING OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): AN EV... 2018
Details P1.09-18 15 CASES OF CLINICAL AND MOLECULAR FEATURES ANALYSIS IN PULMONARY... 2018
Details P2.01-03 QUALITY OF LIFE OUTCOMES FOR FDA-APPROVED AGENTS IN ADVANCED NON-... 2018
Details P2.09-19 UTILISING HETEROGENEITY: USING A DIGITAL DATABASE OF LUNG CANCERS... 2018
Details P3.01-23 IMAGING MODALITIES FOR SURVEILLANCE AND FOLLOW-UP OF PATIENT WITH... 2018
Details P3.13-02 LYMPHOCYTIC PLEVRAL EFFUSION DUE TO CRIZOTINIB USAGE: FIRST CASE ... 2018
Details OA06.03 SUBLOBAR RESECTION IS EQUIVALENT TO LOBECTOMY FOR SCREEN DETECTED ... 2018
Details MA25.06 RPA ANALYSIS FOR OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER: SMOKI... 2018
Details P1.09-20 CORRELATION BETWEEN WHOLE GENOMIC COPY NUMBER VARIANT SCORING AND... 2018
Details P2.01-01 THE IMPACT OF ANLOTINIB ON BRAIN METASTASES OF NSCLC: POST-HOC AN... 2018
Details P2.09-23 A COMBINATION OF PODOPLANIN AND E-CADHERIN EXPRESSION IN LUNG SQC... 2018
Details P3.01-21 METASTATIC LUNG CARCINOMA —AN INSTITUTIONAL EXPERIENCE FROM EAS... 2018
Details P3.13-01 DETECTING ALK REARRANGEMENTS IN NSCLC PATIENTS: IHC, FISH OR NGS ... 2018
Details OA06.02 VIDEO-ASSISTED THORACOSCOPIC SURGERY VS. THORACOTOMY FOR NON-SMALL... 2018
Details MA25.10 COMPLETE RESPONSE BY PET-CT AFTER RADICAL TREATMENT IN OLIGOMETAST... 2018
Details P1.09-23 EFFECT OF PLASMA INPUT ON THE CLINICAL SENSITIVITY OF A REAL-TIME... 2018
Details P2.01-05 ADENOCARCINOMA OF THE LUNG: THE WOMAN’S CANCER?... 2018
Details P2.09-24 MERS67 IS A NOVEL ANTI-NAPI2B ANTIBODY AND DEMONSTRATES DIFFERENT... 2018
Details P3.01-22 AN EXPLORATORY ANALYSIS OF PD-L1 EXPRESSION AND SMOKING HISTORY I... 2018
Details P3.13-05 USE OF CRIZOTINIB IN A PATIENT WITH A ROS MUTATION CAUSING ELEVAT... 2018
Details OA06.06 MISSILE-NSCLC: A PHASE II TRIAL MEASURING THE INTEGRATION OF STERE... 2018
Details MA25.07 EFFECTIVENESS OF SYSTEMIC THERAPY COMBINED WITH THORACIC RADIOTHER... 2018
Details P1.09-24 THE EFFECTS OF NLR AND PLR OF EFFECT ON PROGNOSIS IN PATIENTS WIT... 2018
Details P2.01-06 HSP72 EXPRESSION ASSOCIATES WITH SURVIVAL IN EGFR MUTATED NSCLC... 2018
Details P2.09-21 WOMEN WITH SYNCHRONOUS OR METACHRONOUS LUNG AND OVARIAN CANCERS: ... 2018
Details P3.01-26 A FRAMEWORK FOR SYSTEMATIC CLINICAL EVALUATION OF TECHNICAL INNOV... 2018
Details P3.13-06 ANALYSIS OF ALK REARRANGEMENT NON-SMALL CELL LUNG CANCER CELL BLO... 2018
Details OA06.07 PREDICTORS AND CONSEQUENCES OF REFUSING SURGERY FOR CLINICAL STAGE... 2018
Details MA25.09 M1B DISEASE IN THE 8TH EDITION OF IASLC STAGING OF LUNG CANCER: PA... 2018
Details P1.09-21 CIRCULATING TUMOR DNA IMPROVES GENOTYPIFICATION AND DETECTION OF ... 2018
Details P2.01-04 REDUCING TIME TO MOLECULAR DIAGNOSIS FOR ADVANCED NSCLC IN THE CO... 2018
Details P2.09-22 RELEVANCE OF RESULTS OF INTRAOPERATIVE PLEURAL LAVAGE CYTOLOGY AN... 2018
Details P3.01-24 THE IMPORTANCE TO SWITCH FROM EGFR-TKI TO CYTOTOXIC CHEMOTHERAPY ... 2018
Details P3.13-03 REAL-WORLD ANAPLASTIC LYMPHOMA KINASE TESTING PRACTICES: RESULTS ... 2018
Details OA06.05 DO SBRT PLANNING AND DELIVERY FACTORS INFLUENCE LOCAL CONTROL FOR ... 2018
Details MA26.01 ACCUMULATION OF CONCOMITANT MUTATIONS INVOLVED IN DRUG RESISTANCE ... 2018
Details P1.09-22 DETECTION OF ALK GENE REARRANGEMENT IN FFPE TISSUES OF NON-SMALL ... 2018
Details P2.01-09 TARGETABLE GENOMIC ALTERATIONS IN KRAS MUTANT LUNG ADENOCARCINOMA... 2018
Details P2.09-26 CLINICAL SIGNIFICANCE OF SUBCELLULAR LOCALIZATION OF MASPIN IN PA... 2018
Details P3.01-25 FEASIBILITY OF MODERATE HYPOFRACTIONATED THORACIC IRRADIATION FOR... 2018
Details P3.13-04 LORLATINIB IN ANAPLASTIC LYMPHOMA KINASE AND PROTO-ONCOGENE TYROS... 2018
Details OA07.02 ATOM: A PHASE II STUDY TO ASSESS EFFICACY OF PREEMPTIVE LOCAL ABLA... 2018
Details MA25.11 CLINICAL AND MOLECULAR PREDICTORS OF OUTCOME IN PATIENTS WITH EGFR... 2018
Details P1.09-27 CLEAR CELL ADENOCARCINOMA SUBTYPE IS AN INDEPENDENT PREDICTOR OF ... 2018
Details P2.01-07 SAFETY AND EFFICACY OF LATTICE RADIOTHERAPY IN VOLUMINOUS NON-SMA... 2018
Details P2.09-27 PROGNOSTIC SIGNIFICANCE OF VASCULAR INVASION IN PATHOLOGICAL STAG... 2018
Details P3.01-27 CHARACTERIZATION AND SENSITIZATION OF NON-SMALL CELL LUNG CANCER ... 2018
Details P3.13-09 ALTER-0303 STUDY: TUMOR MUTATION INDEX (TMI) FOR CLINICAL RESPONS... 2018
Details OA07.03 ADDITION OF LOCAL THERAPY TO EGFR TKI SHOWED SURVIVAL BENEFIT IN E... 2018
Details MA26.03 ACTIVITY OF OSIMERTINIB AND THE SELECTIVE RET INHIBITOR BLU-667 IN... 2018
Details P1.09-25 INVASIVE SIZE (NOT TOTAL SIZE) PREDICTS OVERALL SURVIVAL IN INVAS... 2018
Details P2.01-08 CONVERSION SURGERY FOR LOCALLY ADVANCED LUNG ADENOCARCINOMA HARBO... 2018
Details P2.09-25 ABUNDANT TUMOR PROMOTING STROMAL CELLS IN LUNG ADENOCARCINOMA WIT... 2018
Details P3.01-30 TREATMENT SEQUENCING IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE ... 2018
Details P3.13-07 THE EFFECT OF CRIZOTINIB IN PATIENTS OF NON SMALL CELL LUNG CANCE... 2018
Details OA07.01 PHASE II STUDY OF PEMBROLIZUMAB FOR OLIGOMETASTATIC NON-SMALL CELL... 2018
Details MA26.05 COMPREHENSIVE ANALYSIS OF TREATMENT RESPONSE AND PROGRESSION PATTE... 2018
Details P1.09-26 A CASE REPORT OF DISCORDANT MARKERS OF LUNG CANCER TUMOR CELLS: A... 2018
Details P2.01-12 RAMUCIRUMAB+DOCETAXEL USAGE FOLLOWING RAPID DISEASE PROGRESSION I... 2018
Details P2.09-30 CLINICOPATHOLOGICAL INVESTIGATION OF FOUR RESECTED CASES FOR PLEO... 2018
Details P3.01-28 THE CLINICAL IMPACT OF COMPREHENSIVE CFDNA GENOMIC TESTING IN LUN... 2018
Details P3.13-08 ASSESSMENT OF EGFR GENE MUTATIONS IN CF-DNA IN MONITORING OF RESP... 2018
Details OA07.06 EFFICACY OF LOCAL CONSOLIDATIVE THERAPY FOR OLIGOMETASTATIC LUNG A... 2018
Details MA26.09 LAZERTINIB, A THIRD GENERATION EGFR-TKI, IN PATIENTS WITH EGFR-TKI... 2018
Details P1.09-30 HETEROTOPIC EXPRESSION OF CERULOPLASMIN IN LUNG ADENOCARCINOMA AN... 2018
Details P2.01-13 NUMBER, RATHER THAN LOCATION OF METASTASES, DICTATES OUTCOME IN S... 2018
Details P2.09-28 DETECTION OF ISOLATED TUMOR CELLS IN REGIONAL LYMPH NODES FROM PN... 2018
Details P3.01-29 ST.IV LUNG ADENOCARCINOMA TREATED BY FIRST- LINE EGFR–TYROSINE K... 2018
Details P3.13-11 ADVANCED NSCLC TREATED WITH GEFITINIB OR ERLOTINIB FOR FIVE YEARS... 2018
Details OA07.05 LOCAL ABLATIVE THERAPY IMPROVES SURVIVAL IN PATIENTS WITH SYNCHRON... 2018
Details MA26.06 CRIZOTINIB-TREATED ALK IMMUNOPOSITIVE METASTASIZED NSCLC IS ASSOCI... 2018
Details P1.09-31 PRELIMINARY EXPERIENCE WITH LIQUID BIOPSIES IN A RESOURCE CONSTRA... 2018
Details P2.01-10 PROGNOSTIC IMPACT OF LONGITUDINAL MONITORING OF RADIOMIC FEATURES... 2018
Details P2.09-29 AUTOMATIC LUNG CANCER STAGING FROM MEDICAL REPORTS USING NATURAL ... 2018
Details P3.01-33 EGFR MUTATION IN PATIENTS WITH NSCLC AND ITS RELATIONSHIP BETWEEN... 2018
Details P3.13-10 FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL OF STAGE IV NSCLC PATI... 2018
Details OA08.01 LONG-TERM EFFICACY AND SAFETY OF NIVOLUMAB IN SECOND- OR THIRD-LIN... 2018
Details MA26.07 ROS1 (SP384) IMMUNOHISTOCHEMISTRY INTER-READER PRECISION BETWEEN 1... 2018
Details P1.09-28 CLINICAL UTILITY OF RAPID IMMUNOHISTOCHEMISTRY FOR DIFFERENTIATIO... 2018
Details P2.01-11 CHARACTERISTICS OF NON-SMALL CELL LUNG CANCER: DIFFERENCES BY SEX... 2018
Details P2.09-32 DETACHED EPITHELIAL CELL CLUSTER SIZE IN LUNG ADENOCARCINOMA IS A... 2018
Details P3.01-31 PROGNOSTIC FACTORS IN PATIENTS WITH RESECTED PATHOLOGICAL N2 NON-... 2018
Details P3.13-14 IDENTIFICATION OF NOVEL MUTATIONS BY HIGH- THROUGHOUT SEQUENCING I... 2018
Details OA07.07 PFS AND OS BEYOND 5 YEARS OF NSCLC PATIENTS WITH SYNCHRONOUS OLIGO... 2018
Details MA26.11 EFFECTS OF DOSE MODIFICATIONS ON THE SAFETY AND EFFICACY OF DACOMI... 2018
Details P1.09-29 IN SITU GROWTH PATTERN IN LUNG ADENOCARCINOMA IS DIVISIBLE INTO D... 2018
Details P2.01-15 A RADIOLOGIST-LED TRAINING WORKSHOP FOR MR BASED NORMAL TISSUE AN... 2018
Details P2.09-31 CISPLATINUM SUPPRESSED METASTASIS OF NSCLC BY INHIBITING MACROPHA... 2018
Details P3.01-32 AN OPEN-LABEL, NON-RANDOMIZED, BIOMARKER STUDY OF CONCORDANCE IN ... 2018
Details P3.13-12 A LUNG ADENOCARCINOMA WITH CONCOMITANT EGFR AND DE NOVO MET AMPLI... 2018
Details OA08.03 PHASE II TRIAL OF PEMBROLIZUMAB (NCT02399371) IN PREVIOUSLY-TREATE... 2018
Details MA26.10 CNS ACTIVITY OF RAMUCIRUMAB IN COMBINATION WITH OSIMERTINIB IN PAT... 2018
Details P1.09-33 VALIDITY OF NON-SMALL CELL LUNG CANCER NOT OTHERWISE SPECIFIED TO... 2018
Details P2.01-14 PREFERRED AND ACHIEVED GOALS OF PATIENTS WITH METASTATIC LUNG CAN... 2018
Details P2.10-02 VARIATIONS IN SMOKING CESSATION ACTIVITIES AT ONTARIO’S REGIONA... 2018
Details P3.01-36 PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL CE... 2018
Details P3.13-13 AFATINIB IN LUNG ADENOCARCINOMA HARBORING DE NOVO EGFR EXON 20 IN... 2018
Details OA08.05 QUANTIFYING TUMOUR INFILTRATING LYMPHOCYTES (TILS) IN MALIGNANT PL... 2018
Details MA27.03 MULTI-OMIC CHARACTERIZATION OF TKI-TREATED DRUG-TOLERANT CELL POPU... 2018
Details P1.09-34 PROGNOSTIC IMPACT OF INVASIVE SIZE, ACTUAL TUMOR SIZE, AND MUCINO... 2018
Details P2.01-18 DIFFERENTIAL MOLECULAR MECHANISMS ASSOCIATED WITH DRAMATIC AND GR... 2018
Details P2.10-03 FEASIBILITY AND ACCEPTABILITY OF E-CIGARETTES AS AN AID TO QUITTI... 2018
Details P3.01-37 PHASE II STUDY OF AMRUBICIN PLUS ERLOTINIB IN PREVIOUSLY TREATED,... 2018
Details P3.13-16 CONCOMITANT EML4-ALK REARRANGEMENT AND EGFR MUTATION IN NON-SMALL... 2018
Details OA08.02 DREAM - A PHASE 2 TRIAL OF DURVALUMAB WITH FIRST LINE CHEMOTHERAPY... 2018
Details MA27.01 ESTABLISHMENT OF PDX FROM TUMORS CHARACTERIZED BY EGFR MUTATIONS O... 2018
Details P1.09-32 CLASSIFICATION AND MUTATION PREDICTION FROM NON- SMALL CELL LUNG C... 2018
Details P2.01-16 DYNAMIC CTDNA MONITORING REVEALED NOVEL RESISTANCE MECHANISMS AND... 2018
Details P2.10-01 SUCCESS OF A PHARMACY-DRIVEN SMOKING CESSATION PROGRAM... 2018
Details P3.01-34 SHORT HYDRATION REGIMEN WITH A MODIFIED DOSE OF MAGNESIUM SUPPLEM... 2018
Details P3.13-15 FIRST-LINE AFATINIB DOSE INITIATION AND ADJUSTMENT IN PATIENTS WI... 2018
Details OA08.07 IN SILICO DISCOVERY OF UNANNOTATED MIRNAS IN MALIGNANT PLEURAL MES... 2018
Details MA27.02 HYPOFRACTIONATED RADIOTHERAPY NORMALIZES TUMOR VASCULATURE IN NON-... 2018
Details P1.09-36 CLINICAL SIGNIFICANCE OF CANNABINOID RECEPTOR CB2 EXPRESSION IN N... 2018
Details P2.01-17 MALAT1-MIR-101-SOX9 FEEDBACK LOOP MODULATES THE CHEMO-RESISTANCE ... 2018
Details P2.10-06 THE RISK OF LUNG CANCER AMONG WOMEN WHO START SMOKING AS TEENAGER... 2018
Details P3.01-35 OUTCOMES IN ADVANCED NON-SMALL CELL LUNG CANCER AFTER DISCONTINUA... 2018
Details P3.13-19 SURGERY FOR CIIIB LUNG ADENOCARCINOMA AFTER RESPONSE TO ERLOTINI... 2018
Details OA09.01 5AS TO 3AS: EVOLUTION OF THE SYSTEMATIC APPROACH TO SMOKING CESSAT... 2018
Details MA27.07 LUNG ADENOCARCINOMA HARBORING BRAF G469V MUTATION IS UNIQUELY SENS... 2018
Details P1.09-37 TUMOR SPREAD THROUGH AIR SPACES (STAS) IN STAGE I LUNG SQUAMOUS C... 2018
Details P2.01-21 ANTIGEN CASCADE TRIGGERING CORRELATES WITH PROLONGED SURVIVAL IN ... 2018
Details P2.10-04 PATTERN AND FACTORS ASSOCIATED WITH INTENTION TO QUIT TOBACCO USE... 2018
Details P3.01-39 ANALYSIS OF ACQUIRED EGFR T790M MUTATION IN PATIENTS WITH NON-SMA... 2018
Details P3.13-17 A RETROSPECTIVE STUDY: CENTRAL NERVOUS SYSTEM RESPONSE TO OSIMERT... 2018
Details OA08.06 TUMOUR SUPPRESSOR MICRORNAS MODULATE DRUG RESISTANCE BY TARGETING ... 2018
Details MA27.05 DRUG LOADED MESENCHYMAL STEM CELLS FOR TARGETED LUNG CANCER TREATM... 2018
Details P1.09-35 CLINICAL IMPACT OF SYSTEMATIC INFLAMMATION AND HISTOLOGIC GRADE I... 2018
Details P2.01-19 RADIOMICS FEATURES OF CONTRAST ENHANCED CT AS PROGNOSTIC FACTORS ... 2018
Details P2.10-05 PROVIDER MEDICAL SPECIALTY INFLUENCES SMOKING CESSATION COUNSELIN... 2018
Details P3.01-40 TREATMENT OF SUPER ELDERLY PATIENTS FOR NON- SMALL CELL LUNG CANCE... 2018
Details P3.13-18 MECHANISMS OF ACQUIRED RESISTANCE TO AFATINIB CLARIFIED WITH LIQU... 2018
Details OA09.05 POTENTIAL REDUCTION IN LUNG CANCER MORTALITY IN THE US FROM 2015-2... 2018
Details MA27.06 THERAPEUTIC SILENCING OF ONCOGENIC KRAS WITH A MUTANT-SPECIFIC SHO... 2018
Details P1.09-40 METASTATIC ENDOMETRIAL SARCOMA PRESENTING AS A SPONTANEOUS PNEUMO... 2018
Details P2.01-20 FLT-PET FOR DETECTION OF RELAPSE FOLLOWING RADIOTHERAPY FOR LUNG ... 2018
Details P2.10-09 THE BELIEFS, ORIENTATION, KNOWLEDGE, UNDERSTANDING, ATTITUDES AND... 2018
Details P3.01-38 THERAPEUTIC EFFECTS OF FMNP-MSC FOR HYPERTHERMIA ON LUNG CANCER A... 2018
Details P3.13-22 REAL WORLD STUDY OF AFATINIB IN FIRST-LINE OR RE- CHALLENGE SETTIN... 2018
Details OA09.06 MOLECULAR ALTERATIONS AND ESTIMATED INDOOR RADON IN NSCLC PATIENTS... 2018
Details MA27.11 GENOMIC SEQUENCING AND EDITING REVEALED THE GRM8 SIGNALING PATHWAY... 2018
Details P1.09-38 PULMONARY EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) WITH VON RECKLIN... 2018
Details P2.01-24 MLPH ACTIVATES CDC42/PAK1 SIGNALING TO PROMOTE EPITHELIAL–MESEN... 2018
Details P2.10-07 HEALTH PROFESSIONAL’S PERCEPTION TOWARDS SMOKING: A CROSS-SECTI... 2018
Details P3.01-43 PREDICTIVE VALUE OF COMPUTED TOMOGRAPHY CHARACTERISTICS FOR NIVOL... 2018
Details P3.13-23 EGFR-TKIS COMBINED HYDROXYCAMPTOTHECIN IMPROVED OUTCOMES IN EGFR-... 2018
Details PL02.03 BRIGATINIB VS CRIZOTINIB IN PATIENTS WITH ALK INHIBITOR-NAIVE ADVA... 2018
Details OA09.03 DISCUSSIONS BETWEEN HEALTH PROFESSIONALS AND SMOKERS ABOUT E-CIGAR... 2018
Details MA27.09 DUAL INHIBITION OF BCL-XL AND MCL-1 IS REQUIRED TO INDUCE TUMOUR R... 2018
Details P1.09-39 SPREAD THROUGH AIR SPACES PREDICTS A WORSE SURVIVAL IN PATIENTS W... 2018
Details P2.01-25 MICRORNA-330-3P PROMOTES BRAIN METASTASIS OF NON-SMALL CELL LUNG ... 2018
Details P2.10-08 SMOKING PREVENTION PROJECT IN SCHOOL POPULATION: MY HEALTH IS IN ... 2018
Details P3.01-41 ANATOMICAL AND CLINICAL BASIS OF #11 LN BY SYSTEMATIC BILATERAL M... 2018
Details P3.13-20 FREQUENCY OF EGFR MUTATIONS IN PATIENTS WITH ADENOCARCINOMA LUNG ... 2018
Details PL03.06 THE FUTURE OF TARGETED THERAPY... 2018
Details OA10.01 PATIENT PREFERENCES FOR TYROSINE KINASE INHIBITOR TREATMENTS FOR E... 2018
Details MA27.10 EGFR-TARGETED THERAPY ALTERS THE TUMOR MICROENVIRONMENT IN EGFR-DR... 2018
Details P1.11-03 MICRORNA WITH ABILITY TO RECIPROCAL REGULATION OF DICER AND DROSH... 2018
Details P2.01-22 INCREASED INCIDENCE, MORBIDITY AND MORTALITY RATES FOR LUNG CANCE... 2018
Details P2.10-12 PREVALENCE, PATTERN AND FACTORS ASSOCIATED WITH DUAL TOBACCO USE ... 2018
Details P3.01-42 PHASE II TRIAL ALLOWED SURGERY AFTER INDUCTION CHEMOTHERAPY OF CB... 2018
Details P3.13-21 APATINIB PLUS ICOTINIB AS FIRST-LINE THERAPY FOR EGFR CO-MUTATION... 2018
Details PL03.05 IT’S ALL IN THE TISSUE... 2018
Details OA10.02 ONCOGENE-DRIVEN PATIENT GROUPS: A NEW ERA FOR RESEARCH PARTNERSHIP... 2018
Details P1.01-03 EFFECT OF PROPHYLACTIC CRANIAL IRRADIATION ON COGNITIVE FUNCTION ... 2018
Details P1.11-01 THE NELSON TRIAGE ALGORITHM APPLIED TO A CHINESE BIOPSIED POPULAT... 2018
Details P2.01-23 BASELINE PLASMA BIOMARKERS PREDICT LONG-TERM RESPONSES TO ALK-TKI... 2018
Details P2.10-10 LUNG CANCER SURVIVAL IN YOUNGER PATIENTS (<40 YEARS): ANALYSIS OF... 2018
Details P3.01-46 PROGNOSTIC UTILITY OF ADVANCED LUNG CANCER INFLAMMATION INDEX (AL... 2018
Details P3.13-25 DEVELOPMENT OF A COMPREHENSIVE GENOMIC PROFILING SYSTEM TO DETECT... 2018
Details ES01.02 IMAGE INTERPRETATION AND ADVANCES FROM THE PERSPECTIVE OF THE RADI... 2018
Details OA09.07 ASSOCIATION BETWEEN OUTDOOR AIR POLLUTION AND LUNG CANCER IN FEMAL... 2018
Details P1.01-01 ROS1-POSITIVE NON-SMALL CELL LUNG CANCER: REAL- WORLD DATA IN KORE... 2018
Details P1.11-02 PATHOLOGIC COMPARISON OF PREVALENT VS. INCIDENT CT LUNG SCREEN DE... 2018
Details P2.01-28 GENDER AND SYSTEMIC TREATMENT PATTERNS: IMPACTS ON THE OVERALL SU... 2018
Details P2.10-11 IMPACT OF SMOKING ON MULTIPLE PRIMARY CANCERS SURVIVAL – A RETR... 2018
Details P3.01-44 CYFRA 21-1 AS A PREDICTOR TO RESPONSE TO CHEMOTHERAPY AND OVERALL... 2018
Details P3.13-26 OUTCOMES OF PATIENTS WITH METASTATIC LUNG CANCER PRESENTED IN A M... 2018
Details ES01.01 IMAGE QUALITY CHARACTERISTICS AND NODULE GROWTH MEASUREMENT, MEDIC... 2018
Details OA10.06 A FIRST-IN-HUMAN PHASE 1 TRIAL OF THE EGFR-CMET BISPECIFIC ANTIBOD... 2018
Details P1.01-02 LONG-TERM OUTCOMES WITH FIRST-LINE NIVOLUMAB PLUS IPILIMUMAB IN A... 2018
Details P1.11-05 METABOLOMIC PROFILING FOR SECOND PRIMARY LUNG CANCER AMONG LUNG C... 2018
Details P2.01-26 ASSOCIATION OF BASE EXCISION REPAIR GENE POLYMORPHISMS WITH RESPO... 2018
Details P2.10-16 FINDING THE RELATIONS BETWEEN LUNG CANCER AND ASSOCIATED RISK FAC... 2018
Details P3.01-45 MULTIFACTORIAL GENE ALTERATIONS IN EGFR BYPASS PATHWAY ARE INDUCE... 2018
Details P3.13-24 EFFICACY OF EGFR-TKIS COMPARED WITH CHEMOTHERAPY AS FIRST-LINE TH... 2018
Details ES01.03 DEEP MACHINE LEARNING FOR SCREENING LDCT... 2018
Details OA10.04 AFATINIB WITH OR WITHOUT CETUXIMAB FOR EGFR- MUTANT NON-SMALL CELL ... 2018
Details P1.01-04 TREATMENT PATTERNS AND OVERALL SURVIVAL FOLLOWING BIOMARKER TESTI... 2018
Details P1.11-04 SIZE MEASUREMENT VARIABILITY OF SOLID COMPONENT OF LUNG ADENOCARC... 2018
Details P2.01-27 MR, CT AND CONE-BEAM CT FOR LYMPH NODE VISUALISATION IN LOCALLY-A... 2018
Details P2.10-17 ENVIRONMENTAL TOBACCO SMOKE EXPOSURE AND EGFR MUTATIONS IN NON-SM... 2018
Details P3.01-48 THE EFFICIENCY OF LOW-DOSE APATINIB IN TREATMENT OF ADVANCED LUNG... 2018
Details P3.13-28 HETEROGENEITY, PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF PDL1 EXP... 2018
Details ES01.04 MULTI-PHASIC SCREENING - CAN WE ADDRESS COMPETING CAUSES OF MORBID... 2018
Details OA10.05 AN OPEN-LABEL, MULTICENTER, PHASE II SINGLE ARM TRIAL OF OSIMERTIN... 2018
Details P1.01-05 METFORMIN IN COMBINATION WITH CRIZOTINIB FOR THE TREATMENT OF EML... 2018
Details P1.11-08 AI BASED MALIGNANCY PREDICTION OF INDETERMINATE PULMONARY NODULES... 2018
Details P2.01-31 UPDATED EGFR MUTATION FREQUENCY IN 1,689 NSCLC BRAZILIAN PATIENTS... 2018
Details P2.10-13 WHEN LUNG CANCER WAS RARE: AN HISTORICAL STUDY OF PREVALENCE FROM... 2018
Details P3.01-47 CLINICAL CHARACTERISTICS AND OUTCOME FOR PATIENTS WITH ADVANCED L... 2018
Details P3.13-27 CLINICAL OUTCOMES OF PATIENTS WITH LUNG ADENOCARCINOMA HARBORING ... 2018
Details ES02.02 PRO: TO MEDICATE: MANAGING BREATHLESSNESS... 2018
Details OA11.01 ROLE OF POST-OPERATIVE RADIATION IN DIFFERENT HISTOLOGIC SUBGROUPS... 2018
Details P1.01-07 IMMUNE-RELATED PNEUMONITIS IN NSCLC PATIENTS TREATED WITH IMMUNE ... 2018
Details P1.11-09 THE DELAY OF LUNG CANCER DIAGNOSIS DUE TO MISDIAGNOSING AS PULMON... 2018
Details P2.01-29 ECONOMIC ANALYSIS OF OSIMERTINIB IN PREVIOUSLY UNTREATED EGFR-POS... 2018
Details P2.10-14 THE EVALUTION OF RELATIONSHIP BETWEEN RADON GAS AND LUNG CANCERS ... 2018
Details P3.01-51 OUTCOMES WITH SYSTEMIC CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS W... 2018
Details P3.13-29 PATIENT-DERIVED XENOGRAFT MODELS(PDX) OF LUNG SQUAMOUS CELL CARCI... 2018
Details ES02.03 CON: NOT TO MEDICATE: MANAGING BREATHLESSNESS... 2018
Details OA11.02 A POPULATION-BASED STUDY OF INCIDENCE AND SURVIVAL TRENDS OF 1,588... 2018
Details P1.01-08 HYPERRESPONSIVE DISEASE: A NEW PATTERN OF RESPONSE IN NSCLC PATIE... 2018
Details P1.11-06 LUNG CANCER PROBABILITY IN NEW PERIFISSURAL NODULES DETECTED IN A... 2018
Details P2.01-30 APPLICABILITY OF LUNG-MOLGPA INDEX IN NON-SMALL CELL LUNG CANCER ... 2018
Details P2.10-15 RADON: #1 CAUSE OF LUNG CANCER IN NON-SMOKERS... 2018
Details P3.01-49 EFFCIENCY OF LOW-DOSAGE APATINIB MONOTHERAPY IN TREATMENT OF ADVA... 2018
Details P3.13-31 CREATING A PRECISION MEDICINE PIPELINE FOR LUNG CANCERS.... 2018
Details ES02.01 EXPANDING PROS IN DAILY PRACTICE... 2018
Details OA10.07 RESISTANCE MECHANISMS OF OSIMERTINIB IN CHINESE NON-SMALL CELL LUN... 2018
Details P1.01-06 PLINABULIN, A NOVEL IMMUNO-ONCOLOGY AGENT MITIGATES DOCETAXEL CHE... 2018
Details P1.11-07 UTILITY OF THE MAXIMUM CT VALUE IN PREDICTING INVASIVENESS OF PUR... 2018
Details P2.01-34 PROGNOSTIC VALUE OF NEUTROPHIL TO LYMPHOCYTE RATIO FOR METASTATIC... 2018
Details P2.11-02 DIRECT COMPARISON OF NEW SOLID NODULES DETECTED IN WOMEN AND MEN ... 2018
Details P3.01-50 IDENTIFICATION OF EGFR MUTATIONAL PROFILE IN LUNG CANCER MOROCCAN... 2018
Details P3.13-30 DRIVER MUTATION IN HEAVY SMOKER PATIENT WITH SQUAMOUS CELL CARCIN... 2018
Details ES02.04 MOLECULAR TESTING 101 FOR NURSES... 2018
Details OA11.06 TWO BRM PROMOTER POLYMORPHISMS DO NOT PREDICT SUSCEPTIBILITY OR PR... 2018
Details P1.01-10 STAGE III NON-SMALL CELL LUNG CANCER CLINICAL OUTCOMES WITH SURGI... 2018
Details P1.11-11 COMPARING LUNG CANCER DIAGNOSED BY LOW DOSE CT (LDCT), INCIDENTAL... 2018
Details P2.01-32 ECONOMIC EVALUATION OF DIAGNOSTIC PLATFORMS FOR T790M DETECTION I... 2018
Details P2.11-03 CARDIOVASCULAR RISK PREDICTION IN A COMMUNITY- BASED LUNG CANCER S... 2018
Details P3.01-54 A HISTORICAL COMPARISON OF PATIENTS WITH ADVANCED NSCLC HARBORING... 2018
Details P3.13-33 LUNG ADENOCARCINOMA HARBORING RET FUSION AND DRAMATIC RESPONSE TO... 2018
Details ES02.05 STRUCTURED APPROACH FOR DEVELOPING AND IMPLEMENTING AND ADVANCED P... 2018
Details OA11.04 A COMPARATIVE STUDY OF PD-L1 IMMUNOHISTOCHEMICAL ASSAYS WITH FOUR ... 2018
Details P1.01-11 NAMED PATIENT USE PROGRAM FOR AFATINIB IN ADVANCED NSCLC WITH PRO... 2018
Details P1.11-12 INTERROGATION OF AN EXHALED MICRORNA PANEL FOR LUNG CANCER RISK A... 2018
Details P2.01-36 REAL-WORLD TREATMENT PATTERNS IN TREATMENT- NAÏVE ADVANCED NSCLC ... 2018
Details P2.11-01 BLOOD TRANSCRIPTOMICS ENABLES DETECTION OF PRE- INVASIVE & MINIMAL... 2018
Details P3.01-52 THE ROLE OF SERUM CARCINOEMBRYONIC ANTIGEN TO PREDICT THE RESPON... 2018
Details P3.13-32 DRUG SENSITIVITY OF LUNG ADENOCARCINOMA TOWARDS INDUCERS OF EPIGE... 2018
Details ES03.03 WHEN TO REPEAT PLEURAL BIOPSIES... 2018
Details OA11.05 PHASE II STUDY OF SUNITINIB IN PATIENTS WITH THYMIC CARCINOMA PREV... 2018
Details P1.01-09 PEMBROLIZUMAB PLUS IPILIMUMAB OR PLACEBO IN 1L METASTATIC NSCLC W... 2018
Details P1.11-10 OPTIMIZING RADIOMICS FEATURES BY MINIMIZING BOUNDARY EFFECTS AND ... 2018
Details P2.01-35 PREDICTING RISK OF CHEMOTHERAPY-INDUCED SEVERE NEUTROPENIA IN PAT... 2018
Details P2.11-06 A NEW HISTOPLASMOSIS ANTIBODY ENZYME IMMUNOASSAY FOR THE DIAGNOSI... 2018
Details P3.01-53 COMPARISON OF THE TREATMENT EFFICACY OF OSIMERTINIB IN YOUNG AND ... 2018
Details P3.15-01 LONG-TERM OUTCOMES OF PULMONARY METASTASECTOMY: A 12-YEAR DUAL CE... 2018
Details ES03.04 ROLE OF CHEMOTHERAPY IN MESOTHELIOMA WITH MINIMAL BULK DISEASE... 2018
Details OA12.01 PHASE II DATA FOR THE MET INHIBITOR TEPOTINIB IN PATIENTS WITH ADV... 2018
Details P1.01-12 SWITCH MAINTENANCE PEMBROLIZUMAB IN PATIENTS WITH METASTATIC NON ... 2018
Details P1.11-14 RADIOLOGICAL PLEURA-TUMOR PROXIMITY IN PURE-SOLID CLINICAL STAGE ... 2018
Details P2.01-39 CAN BENEFIT OR FUTILITY IN TREATING ADVANCED NSCLC BE DETERMINED ... 2018
Details P2.11-04 TREATMENT CAPACITY REQUIRED FOR IMPLEMENTING LUNG CANCER SCREENIN... 2018
Details P3.01-57 REAL-WORLD (RW) PREDICTORS OF IMMUNO-ONCOLOGY (IO) VS CHEMOTHERAP... 2018
Details P3.13-34 RET GENE, A NEW CHOICE FOR NSCLC... 2018
Details ES03.01 DIAGNOSIS OF MESOTHELIOMA BASED ON CYTOLOGY ALONE... 2018
Details OA12.02 UPDATED ANTITUMOR ACTIVITY OF CRIZOTINIB IN PATIENTS WITH MET EXON... 2018
Details P1.01-13 A STUDY OF S-1 PLUS CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL... 2018
Details P1.11-15 APPLICATION OF LUNG-RADS VS. PAN-CAN NODULE RISK CALCULATION IN T... 2018
Details P2.01-37 A PH 1/2 STUDY OF ORAL SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB32... 2018
Details P2.11-05 RECRUITMENT STRATEGIES FOR THE LUNG CANCER SCREENING PILOT FOR PE... 2018
Details P3.01-58 RELATIVE ABUNDANCE OF EGFR MUTATIONS IN PLASMA PREDICTS TUMOR RES... 2018
Details P3.13-35 ANTITUMOR EFFECT OF NERATINIB TARGETING HER2- ALTERED LUNG CANCER... 2018
Details ES03.05 ROLE OF SURGERY IN T0 MESOTHELIOMA... 2018
Details OA12.03 ACTIVITY OF CRIZOTINIB IN MET OR ROS1 POSITIVE (+) NSCLC: RESULTS ... 2018
Details P1.01-15 ROS1-REARRANGED NON-SMALL CELL LUNG CANCER IS ASSOCIATED WITH HIG... 2018
Details P1.11-13 NONINVASIVE DETECTION OF EARLY STAGE NSCLC EGFR MUTATIONS USING E... 2018
Details P2.01-38 SARCOPENIA IS ASSOCIATED WITH METASTATIC BURDEN AND IS A NEGATIVE... 2018
Details P2.11-07 LUNG CANCER IN A TERTIARY CARE SETTING: SO NEAR, YET SO FAR... 2018
Details P3.01-55 SF2: A PCYT-2 INHIBITOR PROTOTYPE IS CAPABLE OF INDUCING CITOTOXI... 2018
Details P3.15-02 CARBOPLATIN DOSE CALCULATED USING DIFFERENT FORMULA FOR EGFR AND ... 2018
Details ES04.03 OVERCOMING RESISTANCE BY IMPROVING TREATMENT COMPLIANCE... 2018
Details OA12.05 VEMURAFENIB IN PATIENTS HARBORING V600 AND NON V600 BRAF MUTATIONS... 2018
Details P1.01-16 FIRST-LINE PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY IN PD-L1 PO... 2018
Details P1.11-17 DISCRIMINATING LESS INVASIVE LESIONS OF EARLY-STAGE LUNG ADENOCAR... 2018
Details P2.01-42 IMPACT OF TOBACCO SMOKING ON OUTCOMES IN PATIENTS WITH METASTATIC... 2018
Details P2.11-08 TUMOR AUTOANTIBODY PANEL CAN IMPROVE THE ACCURACY OF EARLY DIAGNO... 2018
Details P3.01-56 HYPERPROGRESSION AND PSEUDOPROGRESSION IN PATIENTS WITH NON-SMALL... 2018
Details P3.15-03 CAPTURING THE PATIENT EXPERIENCE FOR THE TREATMENT OF EGFR EXON 2... 2018
Details ES04.01 LIQUID BIOPSIES IN LUNG CANCER... 2018
Details OA12.06 MUTATIONAL LANDSCAPE OF BRAF V600E POSITIVE LUNG CANCER PATIENTS F... 2018
Details P1.01-14 IMMUNOTHERAPY (I) FOR ADVANCED, PRE-TREATED, NON-SQUAMOUS NSCLC (... 2018
Details P1.11-18 A CLASSIFICATION-BASED MACHINE LEARNING METHOD REVEALS EXOSOMAL M... 2018
Details P2.01-40 PROGNOSTIC IMPORTANCE OF SARCOPENI AND INFLAMMATORY STATEMENTS IN... 2018
Details P2.11-11 IDENTIFICATION OF THE GENETIC DETERMINANTS OF SUSCEPTIBILITY TO L... 2018
Details P3.01-60 A NOVEL MET D1246H MUTATION AFTER PROGRESSION OF EGFR-TKI/MET INH... 2018
Details P3.15-05 PATIENT REPORTED OUTCOMES (PROS) AS PERFORMANCE MEASURES AFTER SU... 2018
Details ES05.02 CAN PATIENT GROUPS AND REGULATORY BODIES WORK TOGETHER TO MAKE CLI... 2018
Details OA12.07 CLINICAL ACTIVITY OF LOXO-292, A HIGHLY SELECTIVE RET INHIBITOR, I... 2018
Details P1.01-17 IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH METASTATIC NON-SMA... 2018
Details P1.11-16 MODIFIED LUNG-RADS IMPROVES PERFORMANCE OF SCREENING LDCT IN A PO... 2018
Details P2.01-41 THE ROLE AND MECHANISM OF FBW7 DEFICIENCY IN ADVANCED NON-SMALL C... 2018
Details P2.11-12 METABOLOMIC ANALYSIS IN LUNG CANCER FOR SCREENING AND EARLY DETEC... 2018
Details P3.01-61 EGFR AND KRAS MUTATIONAL STATUS AND SIGNIFICANCE IN GREEK PATIENT... 2018
Details P3.15-04 AN INTERDISCIPLINARY EDUCATIONAL PROGRAM DEDICATED TO NON-SMALL C... 2018
Details ES05.04 CHALLENGES AND SOLUTIONS IN ENGAGING WITH THE HEALTH TECHNOLOGY AS... 2018
Details OA13.03 ANLOTINIB AS THIRD-LINE OR FURTHER-LINE TREATMENT IN RELAPSED SCLC... 2018
Details P1.01-18 IMMUNOSENESCENCE CORRELATES WITH PROGRESSION UPON PD-(L)-1 BLOCKA... 2018
Details P1.11-19 EXPRESSION OF TNFRII IN SERUM IS CORRELATED WITH THE SIGNIFICANT ... 2018
Details P2.01-43 ADSCAN: A RANDOMISED PHASE II STUDY OF ACCELERATED, DOSE ESCALATE... 2018
Details P2.11-09 UNCOMMON EGFR MUTATION ANALYSIS FROM URINE OF LUNG CANCER PATIENT... 2018
Details P3.01-59 COMPARISON OF LOBECTOMY, SEGMENTECTOMY AND WEDGE RESECTION FOR EA... 2018
Details P3.15-08 PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS WITH LUNG RESECTION:... 2018
Details ES05.03 DISCREPANCIES AND SUSTAINABLE ACCESS TO INNOVATIVE THERAPIES: TRAN... 2018
Details OA13.01 THE IMPACT OF [ 18 F]FLUDEOXYGLUCOSE PET/CT IN SMALL- CELL LUNG CAN... 2018
Details P1.01-21 SAFETY OF DURVALUMAB RETREATMENT IN ADVANCED NSCLC PATIENTS WHO P... 2018
Details P1.12-03 A PROSPECTIVE STUDY OF APATINIB IN ADVANCED SMALL CELL LUNG CANCE... 2018
Details P2.01-44 PROGNOSTIC VALUE OF TP53 HOT EXON MUTATION IN PATIENTS WITH ADVAN... 2018
Details P2.11-10 POTENTIAL UTILITY OF A POSITIVE EARLYCDT ® -LUNG BLOOD BIOMARKER... 2018
Details P3.01-63 BASELINE BIOMARKERS FOR OUTCOME OF ADVANCED NSCLC PATIENTS RECEIV... 2018
Details P3.15-06 CAPILLARY LEAK SYNDROME IN A PRIMARY LUNG ADENOCARCINOMA PATIENT ... 2018
Details ES06.02 INTEGRATING NEW SYSTEMIC THERAPY INTO TRIALS IN OMD... 2018
Details OA13.02 TWO NOVEL IMMUNOTHERAPY AGENTS TARGETING DLL3 IN SCLC: TRIALS IN P... 2018
Details P1.01-19 EFFICACY OF TYROSINE KINASE INHIBITORS IN EGFR MUTATED NON-SMALL ... 2018
Details P1.12-01 A SINGLE-ARM MULTI-CENTER PHASE II STUDY OF APATINIB IN PATIENTS ... 2018
Details P2.01-47 CLINICAL OUTCOME AFTER SURGICAL RESECTION OF CLINICAL SINGLE-STAT... 2018
Details P2.11-15 IDENTIFYING PATIENTS FOR WHOM LUNG CANCER SCREENING IS PREFERENCE... 2018
Details P3.01-64 PRELIMINARY DATA OF DIVERSE THERAPIES IN PATIENTS WITH ADVANCED N... 2018
Details P3.15-07 A LITERATURE REVIEW AND ASSESSMENT OF LUNG CANCER QUALITY INDICAT... 2018
Details ES06.01 CURRENT CLINICAL TRIALS IN OLIGOMETASTASES... 2018
Details OA13.07 SURVIVAL OUTCOMES AFTER WHOLE BRAIN RADIOTHERAPY FOR BRAIN METASTA... 2018
Details P1.01-20 PHASE III STUDY COMPARING GEFITINIB (G) TO GEFITINIB COMBINED WIT... 2018
Details P1.12-02 PHASE II STUDY OF AMRUBICIN MONOTHERAPY IN ELDERLY OR POOR-RISK P... 2018
Details P2.01-45 MUTATIONAL AND INFLAMMATORY BIOMARKERS FOR LUNG CANCER PATIENTS W... 2018
Details P2.11-16 COMPARISON OF TWO LUNG CANCER SCREENING PROGRAMS IN ONE MEDICAL C... 2018
Details P3.01-62 A NEW METHOD FOR NON-INVASIVE PREDICTION OF RADIOTHERAPY: SDH5 DE... 2018
Details P3.15-11 ASSOCIATION BETWEEN PERIPHERAL BLOOD RATIOS AND CLINICAL STAGE DI... 2018
Details ES07.01 A MOMENT IN TIME FOR THE UNPLANNED CONVERSATIONS... 2018
Details OA13.05 PROPHYLACTIC CRANIAL IRRADIATION (PCI) FOR LIMITED- STAGE SMALL-CEL... 2018
Details P1.01-23 HIGH PD-L1 EXPRESSION IS LESS COMMON THAN EXPECTED AMONG ADVANCED... 2018
Details P1.12-05 EFFICACY OF PERIOPERATIVE CHEMOTHERAPY FOR HIGH- GRADE NEUROENDOCR... 2018
Details P2.01-46 INVESTIGATING THE EFFECTS OF PRIOR MALIGNANCY ON NSCLC TRIAL ELIG... 2018
Details P2.11-13 PRECISE EARLY DETECTION OF LUNG CANCER AND BLOOD CELL CIRCUIT ... 2018
Details P3.01-65 FIRST-LINE RADICAL LOCAL THERAPY MAY PROVIDE ADDITIONAL SURVIVAL ... 2018
Details P3.15-09 ARE LUNG CANCER PATIENTS RECEIVING EDUCATION MATERIALS? THE HEALT... 2018
Details ES06.04 SURGICAL CONSIDERATIONS IN OMD... 2018
Details MA01.03 AN EXTERNALLY VALIDATED NOMOGRAM FOR PREDICTING DISTANT METASTASIS... 2018
Details P1.01-22 EFFECT OF BASAL LYMPHOPENIA ON OUTCOME OF NON SMALL CELL LUNG CAN... 2018
Details P1.12-04 A PH3 STUDY OF NIRAPARIB AS MAINTENANCE THERAPY IN 1L PLATINUM RE... 2018
Details P2.01-48 PREDICTIVE FACTORS IN NSCLC PATIENTS WITH STAGE IIIB/IV TREATED W... 2018
Details P2.11-14 MALIGNANCY ASSOCIATED CHANGE AND THE LUCED ® TEST FOR DETECTION... 2018
Details P3.01-67 INTEGRATED NETWORK ANALYSIS TO UNDERSTAND THE POTENTIAL MECHANISM... 2018
Details P3.15-10 SURVIVAL IMPACT OF PERIPHERAL BLOOD RATIOS IN LUNG CANCER ACCORDI... 2018
Details ES07.04 LEVERAGING SOCIAL MEDIA TO CHANGE THE PUBLIC CONVERSATION ON LUNG ... 2018
Details MA01.01 PROPOSAL ON INCORPORATING LYMPHOVASCULAR INVASION AS A T-DESCRIPTO... 2018
Details P1.01-26 SINGLE-CENTRE EXPERIENCE OF CLINICAL OUTCOMES FOR ADVANCED LUNG C... 2018
Details P1.12-06A ROVALPITUZUMAB TESIRINE MAINTENANCE THERAPY FOLLOWING 1ST LINE P... 2018
Details P2.01-51 STUDY OF CD26/DPP4 EXPRESSION IN A LARGE SERIES OF NON-SMALL CELL... 2018
Details P2.11-17 MICRORNAS IN EXHALED BREATH CONDENSATE AND BRONCHIAL BRUSHINGS AS... 2018
Details P3.01-68 EARLY SBRT TO THE PRIMARY TUMOR MAY OVERCOME THE ICOTINIB RESISTA... 2018
Details P3.15-13 SURGICAL MANAGEMENT OF HUGE PULMONARY ARTERIOVENOUS MALFORMATIONS... 2018
Details ES07.03 SPECIAL NEEDS AND WELLNESS IN LUNG CANCER PATIENTS - EUROPEAN PERS... 2018
Details MA01.02 HISTOLOGIC SUBTYPING IN PATHOLOGIC STAGE I LUNG ADENOCARCINOMA PRO... 2018
Details P1.01-24 CLINICAL EFFICACY OF IMMUNOTHERAPY IN METASTATIC NON-SMALL CELL L... 2018
Details P1.12-06 PULMONARY NEUROENDOCRINE (CARCINOID) TUMORS: COMMNETS/NANETS ENDO... 2018
Details P2.01-49 COMPARISION OF RADIOTHERAPHY CONCURRENT WEEKLY TREATMENT IN LOCAL... 2018
Details P2.11-18 A COMPREHENSIVE LUNG CANCER SCREENING PROGRAM: 5 YEARS IN REVIEW... 2018
Details P3.01-66 CLINICOPATHOLOGICAL CHARACTERISTICS AND MUTATION STATUS OF PULMON... 2018
Details P3.15-14 USING CREATIVE CO-PRODUCTION TO DEVELOP A TREATMENT DECISION SUPP... 2018
Details ES08.02 IMMUNOTHERAPY... 2018
Details MA01.07 VALIDATION OF RTOG 0813 NORMAL TISSUE CONSTRAINTS FOR PULMONARY TO... 2018
Details P1.01-25 CARBOPLATIN AND PEMETREXED PLUS BEVACIZUMAB AFTER FAILURE OF FIRS... 2018
Details P1.12-08 THE EFFECT OF CISPLATIN VERSUS CARBOPLATIN ON CANCER OUTCOMES FOR... 2018
Details P2.01-50 THROMBOEMBOLISM IN ROS1 REARRANGED NON-SMALL CELL LUNG CANCER... 2018
Details P2.11-19 MICRORNAS AS LIQUID BIOPSY BIOMARKERS FOR EARLY DETECTION IN LUNG... 2018
Details P3.01-71 RESULTS OF EXTENDED RESECTION IN T4 NON-SMALL CELL LUNG CANCER... 2018
Details P3.15-12 SURVIVAL IMPACT OF PATIENT ENROLLMENT IN ANTINEOPLASTIC DRUG TRIA... 2018
Details ES07.05 RESEARCH UPDATE: PATIENT’S PERSPECTIVE ON LIVING WITH MALIGNANT ... 2018
Details MA01.05 OPIOIDS AND SLEEP MEDICATION USE AFTER SURGERY FOR EARLY STAGE LUN... 2018
Details P1.01-29 CRIZOTINIB IN ADVANCED LUNG ADENOCARCINOMA PATIENTS WITH ALK OR R... 2018
Details P1.12-06B ROVALPITUZUMAB TESIRINE VS TOPOTECAN IN PATIENTS WITH ADVANCED S... 2018
Details P2.01-54 PREDICTIVE FACTORS FOR THROMBOEMBOLISM IN ADVANCED LUNG CANCER PA... 2018
Details P2.11-20 LUNG EPICHECK TM - RESULTS OF THE TRAINING AND TEST SETS OF A ME... 2018
Details P3.01-69 STEREOTACTIC ABLATIVE RADIOTHERAPY IMPROVES PROGRESSION-FREE SURV... 2018
Details P3.15-16 MANAGEMENT OF PATIENTS WITH ALK-TRANSLOCATED NSCLC: A SIMULATION-... 2018
Details ES08.03 MESOTHELIOMA, THYMIC EPITHELIAL TUMORS AND OTHERS... 2018
Details MA01.06 EVALUATION OF SAFETY AND EFFICACY IN SURGICAL TREATMENT FOR OCTOGE... 2018
Details P1.01-30 CRIZOTINIB IN ADVANCED NON-ADENOCARCINOMA, NSCLC (NA-NSCLC) PATIE... 2018
Details P1.12-07 TIME TO THE END OF THORACIC RADIOTHERAPY AFFECTS TO SURVIVAL OUTC... 2018
Details P2.01-52 IDENTIFICATION OF LEPTOMENINGEAL METASTASIS- SPECIFIC EXOSOMAL MIR... 2018
Details P2.11-22 USE OF ELECTRONIC MEDICAL RECORDS FOR TOBACCO USE AND LUNG CANCER... 2018
Details P3.01-70 META-ANALYSIS OF METFORMIN IN COMBINATION WITH PLATINUM CHEMOTHER... 2018
Details P3.15-17 LUNG CANCER SYMPTOM BURDEN AND QUALITY OF LIFE: FINDINGS FROM THE... 2018
Details ES08.04 NEOADJUVANT THERAPY... 2018
Details MA01.10 TOXICITY AND LOCAL CONTROL IN “ULTRA- CENTRAL” LUNG TUMORS TREA... 2018
Details P1.01-27 INFLUENCE OF EGFR-TKIS TREATMENT LINES AND PFS ON THE EMERGENCE O... 2018
Details P1.12-11 2010 – 2015 EXTENSIVE STAGE SCLC DIAGNOSES IN A CANADIAN INSTIT... 2018
Details P2.01-53 LOCAL TREATMENT FOR OLIGOPROGRESSION/ OLIGOMETASTASES AFTER FAILUR... 2018
Details P2.11-21 FACTORS PREDICTING ATTRITION IN COMMUNITY-BASED HEALTHCARE NETWOR... 2018
Details P3.01-74 CLINICAL AND RADIOLOGICAL PREDICTORS OF EFFICACY TO NIVOLUMAB IN ... 2018
Details P3.15-15 ALI COULD BE A ONE OF PROGNOSTIC SURVIVAL FACTOR FOR NON-SMALL CE... 2018
Details MTE01.02 LUNG PATIENT DERIVED XENOGRAFT AND ORGANOID... 2018
Details MA01.11 SALVAGE SBRT FOR LOCAL RECURRENCE AFTER PRIMARY SURGICAL RESECTION... 2018
Details P1.01-28 IMPACT OF AFATINIB DOSING ON SAFETY AND EFFICACY REAL-WORLD IN PA... 2018
Details P1.12-09 THE EFFECT OF SITE OF FIRST CHEMOTHERAPY ON SMALL CELL LUNG CANCE... 2018
Details P2.01-57 PROGNOSTIC IMPLICATION OF CLINICAL, IMAGING, AND PATHOLOGIC PARAM... 2018
Details P2.11-24 IMPACT OF SCREENING INTERVAL LENGTH ON NEW NODULES DETECTED IN IN... 2018
Details P3.01-75 RELAY+, AN EXPLORATORY STUDY OF GEFITINIB WITH RAMUCIRUMAB IN UNT... 2018
Details P3.15-19 RISK FACTORS FOR OSTEOPOROSIS IN LUNG CANCER PATIENTS... 2018
Details MTE01.01 GEMM OF LUNG CANCER... 2018
Details MA01.09 RISK FACTORS OF RADIATION-INDUCED LYMPHOPENIA (RIL) AND ITS PROGNO... 2018
Details P1.01-32 A MULTICENTER, OPEN-LABEL, PHASE II TRIAL OF S-1 PLUS CARBOPLATIN... 2018
Details P1.12-10 PATTERNS OF CURATIVE CHEMO-RADIOTHERAPY REGIMEN AND IMPACTS ON TH... 2018
Details P2.01-58 DEMOGRAPHICS, CLINICAL CHARACTERISTICS AND TREATMENT SEQUENCING I... 2018
Details P2.11-23 RISK PERCEPTION AMONG A LUNG CANCER SCREENING POPULATION... 2018
Details P3.01-72 PULMONARY RESECTION IN A PRONE POSITION FOR LUNG CANCER INVADING ... 2018
Details P3.15-20 PALLIATIVE SEDATION IN LUNG CANCER PATIENTS WHOM NEEDS IMMEDIATE ... 2018
Details MTE02.02 UPDATE ON WHO CLASSIFICATION AND STAGING OF LUNG CANCER... 2018
Details MA02.02 MULTISTATE HEALTHCARE NETWORK UNDERUTILIZES VALUABLE END-OF-LIFE R... 2018
Details P1.01-33 RANDOMIZED PHASE 2 STUDY COMPARING CBDCA+PTX+BEV AND CDDP+PEM+BEV... 2018
Details P1.12-12 A SYSTEMATIC REVIEW AND META-ANALYSIS OF EARLY AND LATE SURVIVAL ... 2018
Details P2.01-55 DUAL-ENERGY CT SCAN TO EVALUATE SARCOPENIA IN LUNG CANCER IN COMP... 2018
Details P2.11-27 A RAPID ACCESS LUNG CANCER CLINIC REDUCES VARIATION IN LUNG CANCE... 2018
Details P3.01-73 TALC VERSUS MINOCYCLINE AND OK-432 PLEURODESIS FOR MALIGNANT PLEU... 2018
Details P3.15-18 COMPARISON OF PAIN CONTROL EFFECTS AND SIDE EFFECTS EARLY AFTER V... 2018
Details MTE02.01 UPDATE ON WHO CLASSIFICATION AND STAGING OF LUNG CANCER... 2018
Details MA02.01 ROS1 GENE REARRANGEMENTS ARE ASSOCIATED WITH AN EXAGGERATED RISK O... 2018
Details P1.01-31 WEEKLY REGIMEN OF PAXUS-PM, A NOVEL CREMOPHOR- FREE, WITH CARBOPLA... 2018
Details P1.12-15 DISTINCTIVE CLINICAL CHARACTERISTICS OF SCLC IN NEVER-SMOKERS... 2018
Details P2.01-56 METASTASES IN RESIDUAL PET UPTAKE OF LYMPH NODES AFTER TREATMENT:... 2018
Details P2.11-25 LUNG CANCER SCREENING IMPLEMENTATION IN COMMUNITY PRACTICE: KAISE... 2018
Details P3.01-78 THE CYTOLOGY SAMPLES AND PLASMA SPECIMENS WERE FEASIBLE FOR THE E... 2018
Details P3.15-22 VALIDATION OF EUROLUNG RISK MODELS IN A JAPANESE POPULATION: A RE... 2018
Details MTE03.02 NOVEL TRIAL DESIGN FOR PRECISION MEDICINE... 2018
Details MA02.05 A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 NONINFERIOR... 2018
Details P1.01-35 TUMOR VOLUME ANALYSIS IN ALK-REARRANGED NSCLC TREATED WITH CRIZOT... 2018
Details P1.12-16 MANAGEMENT OF ELDERLY SMALL-CELL LUNG CANCER PATIENTS IN A ROMANI... 2018
Details P2.01-61 BODY MASS INDEX OVER TIME IS ASSOCIATED WITH OVERALL SURVIVAL IN ... 2018
Details P2.11-26 FIRST OF ITS KIND MULTI-PRONGED TRAINING FOR PCPS IN AN EPICENTER... 2018
Details P3.01-76 CLINICAL BACKGROUND AND RESPONSE TO CHEMOTHERAPY IN NSCLC PATIENT... 2018
Details P3.15-23 DATA MINING THE INTERNET AND CROWDSOURCING IN GUIDING PATIENT DEC... 2018
Details MTE03.01 INCLUSION/EXCLUSION UPDATES (CNS METS, MULTIPLE PRIOR CANCERS, OR... 2018
Details MA02.03 ASTRIS: A REAL WORLD TREATMENT STUDY OF OSIMERTINIB IN PATIENTS WI... 2018
Details P1.01-34 DOCETAXEL PLUS RAMUCIRUMAB WITH PROPHYLACTIC PEG-G-CSF SUPPORT FO... 2018
Details P1.12-13 IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE SURVIVAL O... 2018
Details P2.01-59 THE COST OF LUNG CANCER IN THE COUNTY OF GÄVLEBORG – SWEDEN... 2018
Details P2.12-01 EFFICACY OF BELOTECAN AS SECOND-LINE TREATMENT FOR RECURRENT SMAL... 2018
Details P3.01-77 CLINICAL CHARACTERISTICS OF KOREAN LUNG CANCER PATIENTS WITH PROG... 2018
Details P3.15-21 REAL-WORLD EXPERIENCE OF FIRST-LINE AFATINIB TREATMENT IN PATIENT... 2018
Details MTE04.02 WHERE SHOULD HEALTH PROGRAMS SET THRESHOLD FOR TAILORED SCREENING... 2018
Details MA02.07 APREPITANT FOR COUGH SUPPRESSION IN ADVANCED LUNG CANCER: A RANDOM... 2018
Details P1.01-37 BPI-9016M, A NOVEL C-MET INHIBITOR, IN PRETREATED ADVANCED SOLID ... 2018
Details P1.12-14 SURVIVAL OF PATIENTS WITH SMALL-CELL LUNG CANCER UNDERGOING SURGI... 2018
Details P2.01-60 CLINICAL UTILITY OF CIRCULATING TUMOR CELL (CTC) ANALYSIS USING T... 2018
Details P2.11-28 A FOCUS GROUP AND INTERVIEW STUDY TO EXPLORE THE INFORMATION-NEED... 2018
Details P3.01-81 LONG-TERM OUTCOME OF SURGICALLY RESECTED UNSUSPECTED N2 LUNG ADEN... 2018
Details P3.15-25 ASSESSMENT OF DEPRESSION AMONG ADVANCED STAGE LUNG CANCER PATIENT... 2018
Details MTE04.01 COMPARISONS OF RISK MODELS... 2018
Details MA02.08 THE EFFECT OF NABILONE ON APPETITE, NUTRITIONAL STATUS, AND QUALIT... 2018
Details P1.01-36 THORACIC SURGERY IN NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GRO... 2018
Details P1.12-17 OVERALL SURVIVAL AND RECURRENCE AFTER SURGICAL RESECTION OF PURE ... 2018
Details P2.01-62 EXTRACELLULAR VESICLE-BASED EGFR GENOTYPING IN BRONCHOALVEOLAR LA... 2018
Details P2.11-29 IMPACT OF AN INFORMATION-FILM TO PROMOTE INFORMED DECISION-MAKING... 2018
Details P3.01-82 SURVIVAL IMPACT OF SURGERY IN THE TREATMENT OF STAGE IIIB-IVA NON... 2018
Details P3.15-26 SAFETY OF NIVOLUMAB IN THORACIC MALIGNANCIES: RESULTS FROM A SING... 2018
Details MTE05.01 ROLE OF PNEUMONECTOMY IN N2 DISEASE... 2018
Details MA02.06 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF CHEMOTHERA... 2018
Details P1.01-40 RANDOMIZED PHASE II STUDY OF DOCETAXEL PLUS BEVACIZUMAB OR PEMETR... 2018
Details P1.12-20 OVERALL SURVIVAL WITH LURBINECTEDIN PLUS DOXORUBICIN IN RELAPSED ... 2018
Details P2.01-63 ARE HEART DOSES ASSOCIATED WITH SURVIVAL IN NSCLC TREATED WITH PO... 2018
Details P2.12-04 LIPOSOMAL IRINOTECAN VS TOPOTECAN IN PATIENTS WITH SMALL CELL LUN... 2018
Details P3.01-79 INTRACEREBRAL EFFICACY OF IMMUNE CHECK-POINT INHIBITORS IN NSCLC ... 2018
Details P3.15-24 RAMATHIBODI LUNG CANCER CONSORTIUM (RLC) MODEL: MULTIDISCIPLINARY... 2018
Details MTE05.02 ROLE OF PNEUMONECTOMY IN N2 DISEASE... 2018
Details MA02.10 THE FIRST YEAR OF IMPLEMENTING A LUNG CANCER SCREENING PROGRAM IN ... 2018
Details P1.01-38 A PHASE II WITH A LEAD-IN PHASE I STUDY TO EXAMINE SAFETY AND EFF... 2018
Details P1.12-18 OUTCOME IN SMALL CELL LUNG CANCER PATIENTS WITH CEREBRAL RECURREN... 2018
Details P2.01-65 ASSESSMENT OF INDIVIDUAL AND COMBINED OF FIVE SERUM TUMOR MARKERS... 2018
Details P2.12-02 PHASE II STUDY OF COMBINATION OF NAB-PACLITAXEL AND GEMCITABINE F... 2018
Details P3.01-80 RETROSPECTIVE ANALYSIS OF THE IMPACT OF EGFR T790M MUTATION DETEC... 2018
Details P3.15-28 PROGNOSTIC NUTRITIONAL INDEX FOR PREDICTING POSTOPERATIVE COMPLIC... 2018
Details MTE07.01 FROM RADIATION ONCOLOGY PERSPECTIVE... 2018
Details MA03.01 MANCHESTER LUNG CANCER SCREENING: RESULTS OF THE FIRST INCIDENCE S... 2018
Details P1.01-39 COST-EFFECTIVENESS OF CRIZOTINIB VERSUS CHEMOTHERAPY AS FIRST-LIN... 2018
Details P1.12-19 CLINICO-PATHOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOME IN SMA... 2018
Details P2.01-64 PROGNOSTIC VALUE OF PET-CT AFTER INDUCTION CHEMORADIOTHERAPY AND ... 2018
Details P2.12-03 PHASE I/II TRIAL OF 177LU-DOTA0-TYR3-OCTREOTATE (LUTATHERA) AND N... 2018
Details P3.01-84 THE ASSOCIATION OF CDKN2A GENE MUTATION WITH CLINICOPATHOLOGICAL ... 2018
Details P3.15-29 DEFINING THE SYMPTOM BURDEN OF NON-SMALL CELL LUNG CANCER... 2018
Details MTE06.02 HOW TO REGISTER TOXICITY AND GUIDE PATIENTS... 2018
Details MA02.11 ACHIEVING VALUE IN CANCER DIAGNOSTICS: BLOOD VERSUS TISSUE MOLECUL... 2018
Details P1.01-43 NEXT-GENERATION SEQUENCING IN THE EXPLORATION OF GENETIC HETEROGE... 2018
Details P1.13-01 ANTI-EGF ANTIBODIES INCREASE THE EFFECT OF ALK AND MEK INHIBITORS... 2018
Details P2.01-68 CAPTURE-BASED SEQUENCING DEPICTS EVOLUTION CHARACTERISTICS OF PUL... 2018
Details P2.12-05 SUKSES (SMALL CELL LUNG CANCER UMBRELLA KOREA STUDIES): A PHASE I... 2018
Details P3.01-85 REAL-WORLD GEFITINIB 1ST LINE TREATMENT OF PATIENTS WITH ADVANCED... 2018
Details P3.15-27 INITIAL RESPONSE TO FIRST LINE TREATMENT IS THE BEST PREDICTOR OF... 2018
Details MTE08.01 ENHANCING THE NURSE’S ROLE IN TOBACCO PREVENTION AND CESSATION:... 2018
Details MA03.03 PROLONGED LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) SCREENING BEYOND 5 Y... 2018
Details P1.01-41 A PHASE 2 STUDY OF DS-8201A IN HER2-OVEREXPRESSING OR -MUTATED AD... 2018
Details P1.13-02 EXALT3: PHASE 3 RANDOMIZED STUDY COMPARING ENSARTINIB TO CRIZOTI... 2018
Details P2.01-69 EZH2-MEDIATED EPIGENETIC SUPPRESSION OF GDF15 PREDICTS A POOR PRO... 2018
Details P2.12-06 THE EFFICACY OF APATINIB PLUS TOPOTECAN AS LATERLINE THERAPY FOR ... 2018
Details P3.01-83 USE OF BLOOD OUTGROWTH ENDOTHELIAL CELLS AS A CELLULAR CARRIER FO... 2018
Details P3.15-31 BETTER CLINICAL OUTCOMES AND RESISTANCE MECHANISMS OF CRIZOTINIB ... 2018
Details MTE07.02 FROM SURGICAL PERSPECTIVE... 2018
Details MA03.02 PROSPECTIVE EVALUATION OF THE CLINICAL UTILITY OF THE INTERNATIONA... 2018
Details P1.01-42 REAL-WORLD EVALUATION OF TOLERABILITY IN OLDER ADULT PATIENTS ( â... 2018
Details P1.12-21 DEVELOPING A REAL-WORLD 3L COMPARATOR TO CHECKMATE 032: OVERALL S... 2018
Details P2.01-66 COMPARISON OF EGFR MUTATION STATUS IN TISSUE AND PLASMA CELL-FREE... 2018
Details P2.12-09 EFFICACY AND SAFETY OF CARBOPLATIN AND PACLITAXEL FOR PATIENTS PR... 2018
Details P3.01-88 CLINICAL AND MOLECULAR ANALYSIS OF LONG-TERM SURVIVORS WITH ADVAN... 2018
Details P3.15-30 TREATMENT PATTERNS AND SURVIVAL OF PATIENTS WITH STAGE IV NON-SMA... 2018
Details MTE09.01 EVIDENCE BASED MANAGEMENT OF THE PATIENT OVER 80... 2018
Details MA03.07 DEVELOPMENT AND VALIDATION OF DEEP LEARNING MODEL FOR RECOGNITION ... 2018
Details P1.01-44 OUTCOME OF UNCOMMON EGFR MUTATION POSITIVE NEWLY DIAGNOSED ADVANC... 2018
Details P1.13-04 INTEGRIN β 3 INHIBITION ENHANCES THE ANTITUMOR ACTIVITY OF ALK ... 2018
Details P2.01-67 THE PROGNOSTIC ANALYSIS OF LUNG CANCER PATIENTS WITH OCCULT MALIG... 2018
Details P2.12-07 UTILITY OF STEREOTACTIC BODY RADIOTHERAPY IN PULMONARY CARCINOID ... 2018
Details P3.01-89 UPFRONT SURGERY VERSUS NEOADJUVANT TREATMENT FOLLOWED BY SURGERY ... 2018
Details P3.16-03 UNCOMMON EGFR MUTATIONS AS A WORSE PROGNOSTIC FACTOR FOR SURGICAL... 2018
Details MTE09.02 MANAGEMENT OF THE PS 2 PATIENT... 2018
Details MA03.05 NEW SUBSOLID PULMONARY NODULES IN LUNG CANCER SCREENING: THE NELSO... 2018
Details P1.01-45 CRIZOTINIB EFFICACY IN ALK-POSITIVE ADVANCED STAGE NON-SMALL CELL... 2018
Details P1.13-05 INTEGRIN β 3 INHIBITION ENHANCES THE ANTITUMOR ACTIVITY OF ALK ... 2018
Details P2.01-72 BRONCHIAL SLEEVE VS PNEUMONECTOMY: COMPLICATIONS, RECURRENCES AND... 2018
Details P2.12-08 NETWORK META-ANALYSIS OF ANGIOGENESIS INHIBITORS ON SURVIVAL OF P... 2018
Details P3.01-86 TREATMENT OUTCOMES WITH REDUCED FREQUENCY OF NIVOLUMAB DOSING AS ... 2018
Details P3.16-01 A MULTI-OMIC STUDY REVEALS BTG2 AS A RELIABLE PROGNOSTIC MARKER F... 2018
Details MTE10.01 EMERGING TECHNOLOGIES FOR SMALL AND SMALLER LESIONS - UPDATE ON A... 2018
Details MA03.06 DESCRIPTIVE EPIDEMIOLOGY OF SIGNIFICANT INCIDENTAL FINDINGS IN A L... 2018
Details P1.01-48 NAB-PACLITAXEL PLUS GEMCITABINE IN ADVANCED NSCLC AFTER PLATINUM-... 2018
Details P1.13-03 ENSARTINIB TREATMENT BEYOND DISEASE PROGRESSION IN STAGE IV ALK+ ... 2018
Details P2.01-70 TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA- AND/OR INFRATEN... 2018
Details P2.12-11 A PROGNOSTIC MODEL INTEGRATING IMMUNOHISTOCHEMISTRY MARKERS FOR E... 2018
Details P3.01-87 EFFICACY AND SAFETY OF PEMBROLIZUMAB IN NON- SMALL CELL LUNG CANCE... 2018
Details P3.16-02 PHASE III STUDY OF CANAKINUMAB (ACZ885) AS ADJUVANT THERAPY IN PA... 2018
Details MTE11.01 NOVEL THERAPEUTIC TARGETS IN SCLC... 2018
Details MA04.01 CEMIPLIMAB, A HUMAN MONOCLONAL ANTI-PD-1, ALONE OR IN COMBINATION ... 2018
Details P1.01-46 CIRCULATING TUMOR DNA ANALYSIS FOR PREDICTING RESPONSE TO OSIMERT... 2018
Details P1.13-08 DISTRIBUTION, DIFFERENCES IN CLINICAL CHARACTERISTICS AND RESISTA... 2018
Details P2.01-71 CLINICAL OUTCOME OF INDUCTION CHEMORADIOTHERAPY FOLLOWED BY SURGE... 2018
Details P2.12-10 NOVEL PROGNOSTIC MODEL FOR LIMITED-STAGE SMALL- CELL LUNG CANCER... 2018
Details P3.01-91 COMPUTING THE IMPACT OF IMMUNOTHERAPY ON THE NON-SMALL CELL LUNG ... 2018
Details P3.16-05 A NANOTECHNOLOGY-ENABLED STRATEGY FOR IMAGE- GUIDED TRANSBRONCHIAL... 2018
Details MTE11.02 BIOLOGICAL SUBSETS OF SCLC... 2018
Details MA03.09 TRANSCRIPTOME-WIDE ASSOCIATION STUDY REVEALS CANDIDATE CAUSAL GENE... 2018
Details P1.01-47 PHASE I/II TRIAL OF DASATINIB AND OSIMERTINIB IN PATIENTS WITH AD... 2018
Details P1.13-06 FIRST-LINE LORLATINIB VERSUS CRIZOTINIB FOR ADVANCED ANAPLASTIC L... 2018
Details P2.01-75 STUDY OF MOLECULAR ALTERATIONS IN CYTOLOGICAL SMEARS BY FISH IN P... 2018
Details P2.12-12 PLASMA VITAMIN D LEVEL IS AN INDEPENDENT PROGNOSIS FACTOR IN SCLC... 2018
Details P3.01-90 A PHASE II STUDY EVALUATING CONTINUATION OF EGFR- TKIS BEYOND PROG... 2018
Details P3.16-04 COMPARISON OF 2D AND 3D CONSOLIDATION TO TUMOR RATIOS TO PREDICT ... 2018
Details MTE12.02 HOW CAN WE MINIMIZE TOXICITY FOR OUR HIGH RISK PATIENTS?... 2018
Details MA03.10 POPULATION-BASED RELATIVE RISKS FOR LUNG CANCER BASED ON COMPLETE ... 2018
Details P1.01-51 REAL WORLD EXPERIENCE OF PEMBROLIZUMAB IN PATIENTS WITH METASTATI... 2018
Details P1.13-07 EPITHELIAL-MESENCHYMAL TRANSITION INDUCED THE ACQUIRED RESISTANCE... 2018
Details P2.01-76 THE IMPACT OF CONCORDANCE WITH A LUNG CANCER DIAGNOSIS PATHWAY GU... 2018
Details P2.12-13 EFFECTIVENESS OF HYPOFRACTIONATED THORACIC RADIOTHERAPY IN LIMITE... 2018
Details P3.01-93 OSIMERTINIB-RELATED HEMATOLOGICAL AND PULMONARY TOXICITIES IN ADV... 2018
Details P3.16-07 THE IMPACT OF CLINICAL AND MOLECULAR PROFILE OF RESECTED EGFR-MUT... 2018
Details MTE12.01 IS IO AN OPTION FOR PATIENTS WITH CONTRAINDICATIONS (AUTO-IMMUNE ... 2018
Details MA04.03 IMMUNOTHERAPY FOR NON-SMALL CELL LUNG CANCERS (NSCLC) WITH ONCOGEN... 2018
Details P1.01-52 BR-34- RANDOMIZED TRIAL OF DURVALUMAB & TREMELIMUMAB +/- PLATINUM... 2018
Details P1.13-11 PRO-CTCAE TOXICITIES IN ADVANCED NSCLC PATIENTS WITH EGFR MUTATIO... 2018
Details P2.01-73 AUTOMATED IMAGE ANALYSIS TOOL FOR TUMOR VOLUME GROWTH RATE TO GUI... 2018
Details P2.12-15 PROGNOSTIC AND PREDICTIVE COVARIATES IN LIMITED- STAGE SMALL-CELL ... 2018
Details P3.01-92 BLOOD TEST PARAMETERS AS PROGNOSTIC FACTORS IN EGFR-MUTATED NON-S... 2018
Details P3.16-06 DOES COMPREHENSIVE MUTATION ANALYSIS ADD PROGNOSTIC VALUE IN RESE... 2018
Details MTE15.01 IDENTIFYING HIGH RISK PATIENTS: WHAT MAKES A PATIENT TOO HIGH RIS... 2018
Details MA04.02 RESPONSES AND DURABILITY IN NSCLC TREATED WITH PEGILODECAKIN AND A... 2018
Details P1.01-49 IRAE, POSSIBLE PREDICTIVE MARKERS FOR IMMUNE CHECKPOINT INHIBITOR... 2018
Details P1.13-10 AURORA KINASE A DRIVES THE EVOLUTION OF RESISTANCE TO THIRD GENER... 2018
Details P2.01-74 DOCETAXEL-RELATED FEBRILE NEUTROPENIA (FN) AND PATIENT REPORTED S... 2018
Details P2.12-14 STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES IN SMALL CELL LUNG... 2018
Details P3.01-96 CLINICAL CHARACTERISTICS OF NON–SMALL CELL LUNG CANCER HARBORIN... 2018
Details P3.16-08 BASELINE QUALITY OF LIFE IS INFLUENCED BY THE DURATION OF ABSTINE... 2018
Details MTE14.01 NODULE MANAGEMENT (PRO CON DEBATE AND CASE PRESENTATIONS)... 2018
Details MA04.07 MICRORNA-BASED LIQUID BIOPSY COMBINES WITH PD-L1 TUMOR EXPRESSION ... 2018
Details P1.01-50 REAL WORLD EXPERIENCE OF NIVOLUMAB IN PATIENTS WITH METASTATIC NO... 2018
Details P1.13-14 THE MOLECULAR LANDSCAPE OF LUNG ADENOCARCINOMAS WITH ACTIVATING E... 2018
Details P2.01-78 VALIDATION OF INVISIONFIRST CTDNA NGS PROFILING VIA DDPCR TESTING... 2018
Details P2.12-18 INTERSTITIAL LUNG ABNORMALITIES ARE A RISK FACTOR FOR RADIATION P... 2018
Details P3.01-97 WHICH IS BETTER PROGNOSTIC FACTOR, PS, INFLAMMATORY MARKER, OR PD... 2018
Details P3.16-09 HIGH PREOPERATIVE D-DIMER LEVEL PREDICTS EARLY RECURRENCE AFTER S... 2018
Details MTE17.01 LIVING WITH AND BEYOND LUNG CANCER: AN EDUCATION FOR ADVOCATES... 2018
Details MA04.05 OUTCOMES IN NSCLC PATIENTS TREATED WITH FIRST- LINE PEMBROLIZUMAB A... 2018
Details P1.01-54 A PHASE I/IB STUDY OF BINIMETINIB (MEK162), A MEK INHIBITOR PLUS ... 2018
Details P1.13-12 EGFR THERAPY IN ASCL1 POSITIVE LUNG ADENOCARCINOMA... 2018
Details P2.01-77 INTERCONVERSION OF TWO COMMONLY USED PERFORMANCE TOOLS: AN ANALYS... 2018
Details P2.12-19 PROPHYLACTIC CRANIAL IRRADIATION IN EXTENSIVE SMALL CELL LUNG CAN... 2018
Details P3.01-94 SAFETY AND EFFICACY OF FIRST-LINE PEMETREXED VERSUS BEVACIZUMAB-C... 2018
Details P3.16-10 RADIOMIC FEATURES ON CT ARE PROGNOSTIC OF RECURRENCE AS WELL AS P... 2018
Details MTE16.01 PROPER TREATMENT OF LCNEC; CHEMOTHERAPY OR TARGETED THERAPY... 2018
Details MA04.06 PD-1 BLOCKADE PROMOTES HYPERPROGRESSIVE DISEASE IN NSCLC THROUGH M... 2018
Details P1.01-53 BONE METASTASES AND EFFICACY OF IMMUNOTHERAPY IN PATIENTS WITH PR... 2018
Details P1.13-13 POTENT ANTI-TUMOR EFFECT OF GANETESPIB IN ACQUIRED EGFR-TKI RESIS... 2018
Details P2.01-80 PERFORMANCE STATUS AND RESOURCE UTILIZATION IN PATIENTS RECEIVING... 2018
Details P2.12-16 SIGNIFICANT TUMOR REGRESSION AND TOXICITY WITH NIVOLUMAB PLUS IPI... 2018
Details P3.01-95 EGFR GENOTYPE AS A PREDICTOR OF SURVIVAL IN EGFR MUTANT NON-SMALL... 2018
Details P3.16-11 PATTERN OF RECURRENCE OF COMPLETELY RESECTED LUNG ADENOCARCINOMA ... 2018
Details MTE16.02 THE MANAGEMENT OF SMALL CELL LUNG CANCER FOLLOWING FIRST LINE TRE... 2018
Details MA04.11 NEOANTIGEN TARGETING AND T CELL RESHAPING IN RESECTABLE NSCLC PATI... 2018
Details P1.01-55 UNIQUE GENETIC PROFILES FROM CEREBROSPINAL FLUID COULD PREDICT SU... 2018
Details P1.13-17 MULTICENTRE PHASE II TRIAL OF FIRST-LINE AFATINIB IN PATIENTS WIT... 2018
Details P2.01-79 NEUROLOGICAL DEATH IS COMMON IN PATIENTS WITH EGFR MUTANT NON-SMA... 2018
Details P2.12-17 PROPHYLACTIC CRANIAL IRRADIATION CAN NOT PROVIDE SURVIVAL BENEFIT... 2018
Details P3.01-101 A RETROSPECTIVE STUDY OF LUNG CANCER THAT HAS PROGRESSED TO BRAI... 2018
Details P3.16-13 LONG-TERM OUTCOMES OF STEREOTACTIC BODY RADIATION THERAPY FOR STA... 2018
Details MTE18.01 CASE-BASED MANAGEMENT OF PATIENTS WITH INADEQUATE TISSUE FOR MOLE... 2018
Details MA04.09 NEOADJUVANT ATEZOLIZUMAB IN RESECTABLE NON- SMALL CELL LUNG CANCER ... 2018
Details P1.01-57 THE ROLE OF EGFR MUTATION AS A PROGNOSTIC FACTOR IN SURVIVAL AFTE... 2018
Details P1.13-15 DETECTION OF EGFR MUTATIONS IN CFDNA AND DEVELOPMENT OF RESISTANC... 2018
Details P2.01-83 EVALUATION OF DYNAMIC THIOL/DISULPHIDE HOMEOSTASIS IN ADVANCE NON... 2018
Details P2.13-02 ALK-TRANSLOCATION AND BRAIN METASTASES: A RETROSPECTIVE STUDY. CO... 2018
Details P3.01-102 POTENTIAL PREDICTORS OF UNEXPECTED READMISSION AFTER LUNG RESECT... 2018
Details P3.16-14 SBRT IN EARLY STAGES OF LUNG CANCER... 2018
Details MTE20.01 MOLECULAR TESTING IN SMALL SAMPLES... 2018
Details MA04.10 COMPREHENSIVE PERIPHERAL BLOOD IMMUNOPHENOTYPING AND T-CELL CLONAL... 2018
Details P1.01-58 VARIANTS DISTRIBUTION AND HETEROGENEITY OF OUTCOMES TO CRIZOTINIB... 2018
Details P1.13-16 THE DIAGNOSTIC ACCURACY OF CIRCULATING TUMOR DNA FOR THE DETECTIO... 2018
Details P2.01-84 PATTERNS OF CENTRAL NERVOUS SYSTEM METASTASES IN EGFR MUTATED OR ... 2018
Details P2.13-03 REAL-LIFE EXPERIENCE WITH BRIGATINIB IN PRETREATED EML4-ALK TRANS... 2018
Details P3.01-99 EFFECT OF PEMBROLIZUMAB ON PATIENTS HARBORING UNCOMMON EPIDERMAL ... 2018
Details P3.16-12 STANDARD CONVENTIONAL LOBECTOMY VS STEREOTACTIC BODY RADIOTHERAPY... 2018
Details MTE20.02 MOLECULAR TESTING IN SMALL SAMPLES... 2018
Details MA05.02 PACIFIC SUBGROUP ANALYSIS: PNEUMONITIS IN STAGE III, UNRESECTABLE ... 2018
Details P1.01-56 CONCURRENT MUTATIONS IN CHINESE LUNG CANCER PATIENTS CARRYING HER... 2018
Details P1.13-19 TREATMENT CESSATION FOR IMPROVED DETECTION OF EGFR-MUTATED CIRCUL... 2018
Details P2.01-81 TREATMENT OF SUPERIOR SULCUS TUMOR: A TWELVE- YEAR SINGLE-CENTER E... 2018
Details P2.13-01 BRIGATINIB USE IN ENGLAND – WHERE NEXT?... 2018
Details P3.01-100 RISK OF GASTROINTESTINAL AND HEPATIC TOXICITIES IN PATIENTS WITH... 2018
Details P3.16-17 CARDIAC SPARING IN STEREOTACTIC BODY RADIOTHERAPY OF EARLY STAGE ... 2018
Details MTE19.01 HOW I TREAT ADVANCED STAGE THYMIC MALIGNANCY PATIENTS... 2018
Details MA05.01 E6508: PHASE II STUDY OF IMMUNOTHERAPY WITH TECEMOTIDE AND BEVACIZ... 2018
Details P1.01-59 A BETTER REAL WORLD PRACTICE FOR ROS1 POSITIVE NSCLC PATIENTS, DR... 2018
Details P1.13-18 EXPLORING THE RESISTANCE MECHANISM OF OSIMERTINIB AND MONITORING ... 2018
Details P2.01-82 NEUTROPHIL-TO-LYMPHOCYTE RATIO COMPLEMENTS THE PROGNOSTIC ABILITY... 2018
Details P2.13-05 REAL-WORLD CLINICAL BENEFIT OF CONTINUING CRIZOTINIB BEYOND PROGR... 2018
Details P3.01-104 EGFR-RAD51 FUSION VARIANT IN LUNG ADENOCARCINOMA AND RESPONSE TO... 2018
Details P3.16-15 KINETIC ENERGY DISTRIBUTION FOR GATED TECHNIQUE AT LUNG ABLATIVE ... 2018
Details MTE23.01 SURGICAL CONSIDERATIONS FOLLOWING INDUCTION THERAPY FOR STAGE III... 2018
Details MA05.05 PHOTON-BASED CARDIAC SPARING VIA VOLUMETRIC MODULATED ARC THERAPY ... 2018
Details P1.01-60 PREVENTING AND TREATING BRAIN METASTASES WITH THREE FIRST-LINE EG... 2018
Details P1.13-21 CLINICAL EFFICACY AND SAFETY OF APATINIB COMBINED WITH EGFR - TKI... 2018
Details P2.01-85 THE EFFICACY OF THE TRADITIONAL CHINESE MEDICINE AS MAINTENANCE T... 2018
Details P2.13-06 TP53 STATUS IN RELATION TO RESPONSE TO ANTI-ALK AGENTS IN PATIENT... 2018
Details P3.01-105 RETROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY IN CHINESE ELDERLY... 2018
Details P3.16-16 LONG TERM OUTCOMES OF BODY GAMMA-RAY STEREOTACTIC ABLATIVE RADIOT... 2018
Details MTE22.01 INTEGRATION OF CESSATION AND LUNG CANCER SCREENING... 2018
Details MA05.03 IMMUNE MICROENVIRONMENT AND ITS ASSOCIATION WITH ADJUVANT CHEMOTHE... 2018
Details P1.01-63 CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY OF... 2018
Details P1.13-22 CLINICAL FEATURES AND OUTCOMES OF NSCLC PATIENTS WITH UNCOMMON EG... 2018
Details P2.01-86 GENETIC PROFILING OF CIRCULATING CELL-FREE DNA FROM CEREBROSPINAL... 2018
Details P2.13-04 OUTCOMES OF ALK-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) PATIE... 2018
Details P3.01-103 EFFICACY OF CRIZOTINIB IN CHINESE NON-SMALL CELL LUNG CANCER PAT... 2018
Details P3.16-20 FEASIBILITY OF LIMITED RESECTION FOR PERIPHERAL SMALL-SIZED NON-S... 2018
Details MTE24.02 SMALL LUNG TUMOURS: HIGH RISK LESIONS AND CONTRAINDICATIONS TO ST... 2018
Details MA05.09 PFS AND CARDIAC-TOXICITY-ADJUSTED-PFS AS PREDICTORS OF OS IN LOCAL... 2018
Details P1.01-61 CLINICAL CHARACTERIZATION OF ERBB2 EXON 20 INSERTIONS AND HETEROG... 2018
Details P1.13-20 MET PROTEIN EXPRESSION AND ACTIVATION DURING TARGETED THERAPY IN ... 2018
Details P2.01-87 PROFILING THE SYMPTOM BURDEN OF PATIENTS WITH METASTATIC NSCLC RE... 2018
Details P2.13-09 EFFICACY AND SAFETY OF OSIMERTINIB AFTER PRIOR EGFR TKI: ANALYSIS... 2018
Details P3.01-106 REAL-WORLD DATA TO EVALUATE THE CLINICAL BENEFIT OF NGS FOR DIRE... 2018
Details P3.16-21 ROBOTIC THORACIC SURGERY IN LUNG CANCER RESECTION – A COMPREHEN... 2018
Details MTE23.02 SURGICAL CONSIDERATIONS FOLLOWING INDUCTION THERAPY FOR STAGE III... 2018
Details MA05.06 LOCALLY ADVANCED LUNG CANCER RADIOTHERAPY IN DEEP INSPIRATION BREA... 2018
Details P1.01-65 PII OF PEMETREXED OR PEMETREXED PLUS BEVACIZUMAB FOR PREVIOUSLY U... 2018
Details P1.13-23 TP53 MUTATIONS AS MECHANISMS OF PRIMARY AND ACQUIRED RESISTANCE T... 2018
Details P2.01-90 PD-L1 EXPRESSION AS A PREDICTIVE BIOMARKER IN ADVANCED NON-SMALL ... 2018
Details P2.13-07 CUX1-ALK: A NOVEL ALK REARRANGEMENT THAT RESPONDS TO CRIZOTINIB I... 2018
Details P3.01-109 REAL-WORLD PATIENT-REPORTED OUTCOME ASSESSMENT OF PATIENTS WITH ... 2018
Details P3.16-18 MODERN RADIOTHERAPY INCREASES PATIENT ACCESS TO CURATIVE INTENT R... 2018
Details MTE26.01 ONCO-PULMONOLOGIST... 2018
Details MA05.07 DOSE ESCALATED CHEMO-RT TO 84 GY IN STAGE III NSCLC APPEARS EXCESS... 2018
Details P1.01-66 RANDOMIZED PHASE II EVALUATING EGFR-TKI ASSOCIATED WITH ANTI-ESTR... 2018
Details P1.13-26 FIRST-LINE CONTINUAL EGFR-TKI PLUS LAT DEMONSTRATED SURVIVAL BENE... 2018
Details P2.01-88 C-REACTIVE PROTEIN (CRP) AS A PREDICTIVE MARKER FOR SURVIVAL IN P... 2018
Details P2.13-08 PHASE 1 STUDY OF THE AXL INHIBITOR DS-1205C IN COMBINATION WITH O... 2018
Details P3.01-110 DEFINING AGGRESSIVE DISEASE IN PATIENTS WITH ADVANCED NSCLC RECE... 2018
Details P3.16-19 CLINICAL OUTCOMES OF STEREOTACTIC BODY RADIATION THERAPY FOR T2N0... 2018
Details MTE25.01 ENHANCING THE CARE OF YOUR OLDER ADULT POPULATION WITH LUNG CANCE... 2018
Details MA06.01 THE INTRINSIC PD-L1 PROMOTES CELLULAR INVASIVENESS VIA THEIR PD-1 ... 2018
Details P1.01-64 IMPACT OF STK11 CO-MUTATION ON OUTCOMES FOLLOWING IMMUNOTHERAPY A... 2018
Details P1.13-24 EGFR-KDD IS RARE AND DEMONSTRATES VARIABLE ANTI- TUMOR RESPONSE TO... 2018
Details P2.01-89 SYNERGISTIC CYTOTOXICITY THROUGH MAPK/ERK PATHWAY AND ALK INHIBIT... 2018
Details P2.13-12 THE DENOVO T790M MUTATION RECOVERED BY DDPCR IS ASSOCIATED WITH A... 2018
Details P3.01-107 CORRELATION STUDY OF BONE METASTASIS AND CHOLESTEROL LEVEL IN PA... 2018
Details P3.16-24 PROGNOSTIC VALUE OF POSITIVE LYMPH NODE RATIO IN NON-SMALL CELL L... 2018
Details MTE28.01 LESSONS FROM THE PAST-WHAT I WOULD NOT DO AGAIN IN DIAGNOSTIC AND... 2018
Details MA05.10 THE PATHOLOGIC RESPONSE OF LOCALLY ADVANCED NSCLC TREATED WITH CON... 2018
Details P1.01-68 CORRELATION OF THE LUNG IMMUNE PROGNOSTIC INDEX (LIPI) AND PDL1 S... 2018
Details P1.13-25 EFFICACY AND SAFETY OF OSIMERTINIB IN EGFR T790M- POSITIVE ADVANCE... 2018
Details P2.01-91 TREATMENT PATTERNS IN PATIENTS WITH STAGE IIIB-IV NSCLC IN CLINIC... 2018
Details P2.13-10 PH I/II STUDY OF ORAL SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB324... 2018
Details P3.01-108 ONCOLOGIST TREATMENT CONSIDERATIONS AND SELECTION IN EGFR M+ NSC... 2018
Details P3.16-22 WEDGE RESECTION FOR SMALL PULMONARY LESIONS WITH PREOPERATIVE BRO... 2018
Details MTE27.01 RADIOTHERAPY IN ES-SCLC... 2018
Details MA05.11 RADIOMICS ANALYSIS USING SVM PREDICTS MEDIASTINAL LYMPH NODES STAT... 2018
Details P1.01-67 CLINICAL RELEVANCE OF ALK/ROS1 RESISTANCE MUTATIONS AND OTHER ACQ... 2018
Details P1.13-29 OVERALL RESPONSE RATE OF NINTEDANIB AND DOCETAXEL IN COMBINATION ... 2018
Details P2.01-94 DIAGNOSTIC PATTERNS OF NON-SMALL CELL LUNG CANCER AT PRINCESS MAR... 2018
Details P2.13-11 EGFR AMPLIFICATION AND SENSITIZING MUTATIONS CORRELATES WITH SURV... 2018
Details P3.01-113 A MULTICENTER SURVEY OF ONE YEAR SURVIVAL AMONG CHINESE PATIENTS... 2018
Details P3.16-26 ANATOMIC SEGMENTECTOMY IN STAGE I NON-SMALL- CELL LUNG CANCER REVE... 2018
Details GR01.02 SURGICAL ONCOLOGY... 2018
Details MA06.03 PD-1 AND ID-1 COMBINED BLOCKADE IMPACTS TUMOR GROWTH AND SURVIVAL ... 2018
Details P1.01-71 CO-MUTATIONS, NATURAL HISTORY, AND OUTCOMES OF BRAF-MUTATED NON-S... 2018
Details P1.13-27 A RANDOMIZED STUDY OF CONCURRENT VS SEQUENTIAL ALTERNATING EGFR-T... 2018
Details P2.01-92 “ALL-IN-ONE” WINDOW: A NEW WAY OF LOOKING AT CHEST CT STUDIES... 2018
Details P2.13-15 SHORT-TERM RESPONDERS OF NSCLC TO EGFR-TKIS DISPLAY HIGH PREVALEN... 2018
Details P3.01-111 EFFICACY AND SAFETY OF CYTOTOXIC DRUG CHEMOTHERAPY AFTER FIRST-L... 2018
Details P3.16-27 CLINICAL OUTCOME OF PREOPERATIVE INTERVENTION BRONCHOSCOPY FOLLOW... 2018
Details GR01.04 MEDICAL ONCOLOGY... 2018
Details MA06.02 PROSPECTIVE IMMUNOGENOMIC PROFILING OF NON- SMALL CELL LUNG CANCER:... 2018
Details P1.01-69 VALIDATION OF THE LUNG IMMUNE PROGNOSTIC INDEX (LIPI): USEFUL TO ... 2018
Details P1.13-28 THE FUNCTIONAL MDM4 GENETIC POLYMORPHSIM AS PROGNOSTIC BIOMARKER ... 2018
Details P2.01-93 THE ANALYSIS OF THE SOLUBLE PROGRAMMED DEATH-1 OF LUNG CANCER PAT... 2018
Details P2.13-16 PREFERENCE OF ADJUVANT TREATMENTS FOR EGFR- MUTANT RESECTED NSCLC ... 2018
Details P3.01-112 THE PROGNOSIS OF LUNG CANCER PATIENTS WITH UNEXPECTED MALIGNANT ... 2018
Details P3.16-25 IMPACT OF DIABETES MELLITUS ON SURVIVAL OUTCOME IN PATIENTS WITH ... 2018
Details GR01.03 SURGICAL ONCOLOGY... 2018
Details MA06.07 GENETIC AND EPIGENETIC ALTERATIONS ARE ASSOCIATED WITH TUMOR MUTAT... 2018
Details P1.01-70 EFFICACY AND SAFETY OF SECOND- OR THIRD-LINE NAB- PACLITAXEL + DUR... 2018
Details P1.13-30 NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR AND ITS REL... 2018
Details P2.01-96 DYSGEUSIA ASSOCIATED WITH NUTRITIONAL AND QUALITY OF LIFE PARAMET... 2018
Details P2.13-14 THE CLINICAL USEFULNESS OF LIQUID BIOPSY FOR DETECTION AND DYNAMI... 2018
Details P3.01-115 LIPOSOMAL PACLITAXEL VERSUS GEMCITABINE: WHICH IS BETTER?... 2018
Details P3.16-30 THE IMPACT OF THE SURGICAL APPROACH ON LYMPH NODE UPSTAGING IN CU... 2018
Details GR02.01 CASE 1: SINGLE ZONE N2 (NO PNEUMONECTOMY NECESSARY)... 2018
Details MA06.05 THE MICRO-ENVIRONMENTAL CROSS TALK BETWEEN MAST CELLS AND LUNG CAN... 2018
Details P1.01-73 PRELIMINARY RESULTS OF THE SENECA (SECOND LINE NINTEDANIB IN NON-... 2018
Details P1.13-33 EX VIVO 2*2*2 TUMOR TISSUE EXPLANT CULTURE FOR PRECISION MEDICINE... 2018
Details P2.01-95 ASSESMENT THE FITNESS FOR CHEMOTHERAPY OF NSCLC PATIENTS USING 6M... 2018
Details P2.13-18 A MULTICENTER PROSPECTIVE BIOMARKER STUDY TO EXPLORE MECHANISMS O... 2018
Details P3.01-116 RANDOMIZED CLINICAL TRIAL ON THREE DIFFERENT PLATINUM BASED CHEM... 2018
Details P3.16-28 SURGERY OF STAGE I NON-SMALL CELL LUNG CANCER IN PATIENTS AGED 70... 2018
Details PC01.01 PRO INTRAPLEURAL CHEMOTHERAPY IS IT THE FUTURE?... 2018
Details MA06.06 AN EX-VIVO PATIENT-DERIVED, IMMUNOCOMPETENT (PDI) CULTURE SYSTEM T... 2018
Details P1.01-72 FIND TRIAL: A PHASE II STUDY TO EVALUATE THE EFFICACY OF THE FGFR... 2018
Details P1.13-34 CHANGES IN RADIOMIC FEATURES BETWEEN BASELINE AND TWO WEEKS POST-... 2018
Details P2.01-99 CAN NGS NSCLC TESTING BE IMPLEMENTED WITHOUT IN HOUSE EXPERTISE? ... 2018
Details P2.13-17 NON-SMALL LUNG CANCER IN THE VERY YOUNG: MORE EGFR/ALK MUTATION R... 2018
Details P3.01-114 DISSOCIATION OF HEART AND GREAT VESSELS FOR LONG TRACHEAL TUMORS... 2018
Details P3.16-29 PREDICTION OF LYMPH NODE METASTASES IN CLINICAL T1AN0M0 NON-SMALL... 2018
Details PC01.03 PRO IO IN MESOTHELIOMA SHOULD ONLY BE GIVEN ON CLINICAL TRIALS... 2018
Details MA06.11 DISTINCT ORIGINS OF LYMPHATIC AND BRAIN METASTASIS IN LUNG CANCER... 2018
Details P1.01-76 A PHASE II TRIAL OF ALBUMIN-BOUND PACLITAXEL AND GEMCITABINE IN P... 2018
Details P1.13-31 SAFETY AND TUMOUR HYPOXIA MODIFYING EFFECT OF BUPARLISIB WITH RAD... 2018
Details P2.01-100 DIFFERENT GENETIC MUTATIONS ENRICHED IN CIRCULATING TUMOR DNA PR... 2018
Details P2.13-19 PROGNOSTIC VALUE INFERRED FROM THE QUANTITATIVE MEASUREMENT OF EG... 2018
Details P3.03-02 SINGLE-CELL RNA-SEQ IN HUMAN LUNG CANCER... 2018
Details P3.16-33 CHARACTERISTICS AND RISK FACTORS OF RECURRENCE AFTER SEGMENTECTOM... 2018
Details PC02.01 SURGERY - PRO... 2018
Details MA06.09 XRCC6BP1: A DNA REPAIR GENE IN CISPLATIN RESISTANT LUNG CANCER STE... 2018
Details P1.01-74 MET EXON 14-ALTERED LUNG CANCERS: CENTRAL NERVOUS SYSTEM (CNS) ME... 2018
Details P1.13-32 COMPARISON BETWEEN IMMUNE-MEDIATED PNEUMONITIS AND PNEUMONIA IN P... 2018
Details P2.01-97 PROGNOSTIC FACTORS IN RESECTED LUNG MUCINOUS ADENOCARCINOMA: CLIN... 2018
Details P2.13-20 THE COMPARATIVE EFFECTIVENESS OF GEFITINIB VERSUS ERLOTINIB ON TH... 2018
Details P3.03-03 DIFFERENTIAL MICROBIOTA FEATURES IN LUNG TUMOR AND ADJACENT NORMA... 2018
Details P3.16-31 YOUNGER PATIENTS OPERATED FOR LUNG CANCER HAVE BETTER OVERALL SUR... 2018
Details PC01.04 CON IN MESOTHELIOMA SHOULD ONLY BE GIVEN ON CLINICAL TRIALS... 2018
Details MA06.10 GERMLINE MUTATION IN ATM AFFECT LUNG CANCER RISK WITH HIGH EFFECT... 2018
Details P1.01-75 UTILITY OF CFDNA TESTING FOR ACQUIRED RESISTANCE: THE MEMORIAL SL... 2018
Details P1.13-36 RANDOMIZED PHASE 2 TRIAL OF SERIBANTUMAB IN COMBINATION WITH ERLO... 2018
Details P2.01-98 SINGLE-ISOCENTER VOLUMETRIC-MODULATED ARC RADIOSURGERY FOR NON-SM... 2018
Details P2.13-23 OSIMERTINIB TREATMENT RESULT OF PLASMA T790M POSITIVE IN DIFFEREN... 2018
Details P3.03-01 BRAF V600 AND NON-V600 MUTATIONS IN CHINESE LUNG CANCER... 2018
Details P3.16-32 A STUDY OF POSTOPERATIVE RECURRENCE IN PATHOLOGICAL STAGE 1 NON-S... 2018
Details PC01.05 PRO RADIATION OPTIONS: ARE WE SMART ENOUGH?... 2018
Details MA07.05 PSYCHOSOCIAL NEEDS AND PROGRAMS OF CANCER PATIENTS/SURVIVORS AND T... 2018
Details P1.01-78 THE INCIDENCE OF BRAIN METASTASES IN ROS1- REARRANGED NON-SMALL CE... 2018
Details P1.13-35 HYPOXIA MAPPING USING OXYGEN-ENHANCED MRI IN LUNG CANCER... 2018
Details P2.01-102 COMPREHENSIVE NEXT-GENERATION SEQUENCING GUIDED TARGETED THERAPI... 2018
Details P2.13-21 MET ADDICTION CAN BE CIRCUMVENTED THROUGH EGFR INHIBITION VIA AXL... 2018
Details P3.03-06 DIFFERENTIALLY EXPRESSED MICRORNAS IN LUNG ADENOCARCINOMA INVERT ... 2018
Details P3.16-36 ADJUVANT CHEMOTHERAPY MAY IMPROVE THE OUTCOME OF PATIENTS WITH NO... 2018
Details PC02.04 BID RADIATION - PRO... 2018
Details MA07.02 LINE OF THERAPY AND PATIENT PREFERENCES TREATING LUNG CANCER: A DI... 2018
Details P1.01-79 CHECKMATE 817: SAFETY OF FLAT-DOSE NIVOLUMAB PLUS WEIGHT-BASED IP... 2018
Details P1.13-39 EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION AMONG NON-SMALL CELL LU... 2018
Details P2.01-101 DYNAMIC MONITORING OF GENE ALTERATIONS WITH CTDNA BY NGS FOR EGF... 2018
Details P2.13-22 RESISTANT PATTERNS TO OSIMERTINIB IN NON-SMALL CELL LUNG CANCER P... 2018
Details P3.03-07 CO-OCCURRING GENOMIC ALTERATIONS IN EGFR ALTERED CHINESE LUNG ADE... 2018
Details P3.16-34 THE IMPACT OF PREOPERATIVE EXERCISE THERAPY ON THE SURGICAL OUTCO... 2018
Details PC03.01 POST-OPERATIVE RADIATION THERAPY OR NOT: PRO... 2018
Details MA07.03 ATTITUDES TO LUNG CANCER IN EUROPE: FINDINGS FROM A GLOBAL CONSUME... 2018
Details P1.01-77 OSIMERTINIB IN THE FIRST-LINE TREATMENT OF NON- SMALL CELL LUNG CA... 2018
Details P1.13-37 CLINICAL EVALUATION OF PLASMA-BASED (CFDNA) GENOMIC PROFILING IN ... 2018
Details P2.01-105 TUMOR TREATING FIELDS PLUS STANDARD OF CARE FOR NON-SMALL CELL L... 2018
Details P2.13-26 IMPACT OF CONCURRENT TUMOR SUPPRESSOR GENE MUTATION ON CLINICAL O... 2018
Details P3.03-04 IS THE CILIARY FUNCTION OF THE LESION BRONCHUS MAINTAINED IN PATI... 2018
Details P3.16-35 STAIR CLIMBING EXERCISE MAY AMELIORATE PULMONARY FUNCTION IMPAIRM... 2018
Details PC02.03 BID RADIATION - CON... 2018
Details MA07.09 WILLINGNESS TO PERFORM MULTIPLE BIOPSIES TO IMPROVE QUALITY OF LUN... 2018
Details P1.01-81 PHASE 3 STUDY OF PEMETREXED-PLATINUM WITH OR WITHOUT PEMBROLIZUMA... 2018
Details P1.13-38 INTER-ORGAN HETEROGENEITY ON MECHANISMS OF TARGETED DRUG RESISTAN... 2018
Details P2.01-103 NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTOR OF IMMUNOTHERAPY T... 2018
Details P2.13-24 PROSPECTIVE EFFICACY OF OSIMERTINIB IN CIRCULATING TUMOUR DNA (CT... 2018
Details P3.03-05 COMPARATIVE TRANSCRIPTOMIC ANALYSIS OF LUNG- IPSC, NSCLC, AND SCLC... 2018
Details P3.16-37 COMPARISON OF LONG-TERM OUTCOMES BETWEEN VATS AND OPEN LOBECTOMIE... 2018
Details PC03.07 ADJUVANT CHEMOTHERAPY FOR THYMIC CARCINOMA - YES... 2018
Details MA07.10 UTILIZING A PERSONALIZED NAVIGATION PROGRAM TO IDENTIFY BARRIERS A... 2018
Details P1.01-82 RISK OF NOT RECEIVING 2ND LINE THERAPY IS HIGH IN EGFR MT+ PTS: R... 2018
Details P1.13-40 RAPID, ROBUST AND DURABLE RESPONSES TO LAROTRECTINIB IN PATIENTS ... 2018
Details P2.01-104 PLASMA T-CELL-DERIVED CIRCULATING DNA IN ADVANCED NSCLC IS NOT C... 2018
Details P2.13-25 ANALYSIS OF EGFR MUTATIONS USING CIRCULATING TUMOUR DNA (CTDNA) I... 2018
Details P3.03-09 MOLECULAR SPECTRUM OF KIT MUTATIONS DETECTION IN CHINESE NON-SMAL... 2018
Details P3.16-38 SYSTEMATIC REVIEW AND META-ANALYSIS OF METHODS TO PREDICT POSTOPE... 2018
Details PC03.02 POST-OPERATIVE RADIATION THERAPY OR NOT: CON... 2018
Details MA07.06 TELEPHONIC COMMUNICATION IN PALLIATIVE CARE FOR BETTER MANAGEMENT ... 2018
Details P1.01-80 ELIOS: A MULTICENTER, OPEN-LABEL, MOLECULAR PROFILING STUDY OF PA... 2018
Details P1.13-41 IN VITRO EVALUATION FOR OPTIMAL MET-TKI SELECTION IN LUNG CANCERS... 2018
Details P2.01-107 ANALYSIS OF MUTATION DETECTION BY CTDNA ON THE BASIS OF METASTAT... 2018
Details P2.13-28 COMPARISON OF DDPCR AND NGS IN LIQUID BIOPSY TO PATHOLOGY RESULTS... 2018
Details P3.03-10 TRANSCRIPTOMIC DIFFERENCES BETWEEN EARLY AND LATE STAGE LUNG ADEN... 2018
Details P3.16-41 POSTOPERATIVE PEMBROLIZUMAB FOR THE PATIENTS WITH PATHOLOGIC STAG... 2018
Details PC03.05 DEBATE ON STANDARD SURGICAL APPROACHES - OPEN THYMECTOMY... 2018
Details MA07.07 IDENTIFYING THE SEVERITY OF PSYCHOSOCIAL SYMPTOMS AMONG PATIENTS D... 2018
Details P1.01-84 HIGH BASAL SERUM EGF LEVELS PREDICTS RESPONSE TO CIMAVAX-EGF, A T... 2018
Details P1.13-44 SAFETY, PK, AND PRELIMINARY ANTITUMOR ACTIVITY OF THE ORAL EGFR/H... 2018
Details P2.01-108 TEMPORAL HETEROGENEITY OF RESISTANT MUTATIONS IN SEQUENTIAL ALK ... 2018
Details P2.13-29 IL-22 CONFERS RESISTANCE TO EGFR-TKIS IN NON- SMALL CELL LUNG CANC... 2018
Details P3.03-08 ANALYSIS OF ESR1 MUTATION SPECTRUM FROM NON- SMALL-CELL LUNG CANCE... 2018
Details P3.16-42 EARLY STAGE NON-SMALL CELL LUNG CANCER SURVIVAL IN A CHILEAN PRIV... 2018
Details PC04.01 OPTIMAL SEQUENCING OF EGFR TKI THERAPY (GEFITINIB/ ERLOTINIB/AFATIN... 2018
Details MA08.02 PROPHYLACTIC CRANIAL IRRADIATION REDUCES THE RISK OF BRAIN METASTA... 2018
Details P1.01-85 THE PREVALENCE OF DIFFERENT EGFR EXON20 MUTATIONS IN 12,833 CHINE... 2018
Details P1.13-42 ACTIVITY OF NOVEL HER2 INHIBITOR, POZIOTINIB, FOR HER2 EXON 20 MU... 2018
Details P2.01-106 A COMPARATIVE ANALYSIS OF GENOMIC ALTERATIONS BY TUMOR TISSUE AN... 2018
Details P2.13-27 DEVELOPMENT, INTERNAL VALIDATION, AND CALIBRATION OF A RISK SCORE... 2018
Details P3.03-12 CYCLIC MECHANICAL STRAIN AND MYOFERLIN MODULATES LUNG ADENOCARCIN... 2018
Details P3.16-39 WHICH SURGERY FOR GROUND GLASS OPACITY LUNG NODULES?... 2018
Details PC03.08 ADJUVANT CHEMOTHERAPY FOR THYMIC CARCINOMA - NO... 2018
Details MA07.11 DRUG PRICE COMPARISON IN ADVANCED LUNG CANCER – HIGH COST PRICES... 2018
Details P1.01-83 IMPOWER150: IMPACT OF CHEMOTHERAPY CYCLES IN 1L METASTATIC NSCLC ... 2018
Details P1.13-43 MOLECULAR AND IMAGING PREDICTORS OF RESPONSE TO ADO-TRASTUZUMAB E... 2018
Details P2.01-111 CLINICAL FEATURES AND PROGNOSIS OF EIGHTY-FIVE PATIENTS WITH PRI... 2018
Details P2.13-30 HIGH-DOSE ICOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EG... 2018
Details P3.03-11 LUNG CANCER STEM CELLS ON IMMUNE MODULATION IN TUMOROUS MICROENVI... 2018
Details P3.16-40 DELAYED CUT-END RECURRENCE AFTER WEDGE RESECTION FOR PULMONARY GR... 2018
Details PC04.03 ADJUVANT TARGETED THERAPY FOR PTS WITH GENOMIC ALTERATIONS - YES... 2018
Details MA08.01 PHASE 3 TRIAL OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT ERLOTINI... 2018
Details P1.01-86 BTCRC-LUN15-017: PHASE-IB STUDY OF IMPRIME PGG AND PEMBROLIZUMAB ... 2018
Details P1.14-01 CURRENT PRACTICES IN THE MANAGEMENT OF MALIGNANT PERICARDIAL EFFU... 2018

1 2 3 4 5 6 7 8 Next